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 Mitochondria are organelles critical for many cellular functions including 
energy production, ion homeostasis, cellular protein trafficking, and apoptosis 
induction. While the mitochondrial protein machinery that performs these roles 
has been studied for many years, the functions of many of these proteins have 
not been fully elucidated.  
 This dissertation is focused on understanding the functions of two 
proteins in mitochondria, and their involvement in disease. We describe a 
novel function for estrogen receptor beta (ERβ) in brain mitochondria. We find 
that ERβ modulates cyclophilin D-dependent mitochondrial permeability 
transition (MPT) in brain. MPT is critical in cell death following brain injuries, 
such as stroke. Based on sex differences in ERβ modulation of MPT, we 
suggest that it may contribute to sex differences in cellular responses to 
ischemia.  
 We also explore the protein CHCHD10, a mitochondrial protein with yet 
unknown function. This protein is of particular interest, as its mutations have 
been recently associated with familial myopathy and neurodegenerative 
diseases, such as ALS. We find that CHCHD10 binds to its homolog 
CHCHD2, and both of these proteins bind to the mitochondrial protein P32. 
 
 
Transient silencing of CHCHD10 expression in HEK293 cells triggers the 
induction of mitochondria-dependent apoptosis. We also generated and began 
to characterize the first CHCHD10 knockout mouse model. Data from the 
cellular and mouse models suggest different yet similar roles for CHCHD10 
and CHCHD2 in mitochondria. 
Uncovering these functions and understanding the pathways that these 
proteins participate in is critical to understanding of basic biology, but also of 
the pathophysiology of disease, as the brain relies heavily on mitochondria, 
and mitochondrial dysfunction occurs in many neurodegenerative diseases. 
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1.  INTRODUCTION 
 
1.1.  Mitochondrial structure and function 
The mitochondrion is a specialized double-membrane organelle in 
eukaryotic cells. Mitochondria form a dynamic, motile network that is a key 
player in many cellular processes, including ATP synthesis, fatty acid 
oxidation, calcium buffering, reactive oxygen species production, and 
apoptosis. 
1.1.1.  Mitochondrial structure 
Mitochondria are structured in subcompartments, which include outer 
membrane (OM), inner membrane (IM), intermembrane space (IMS) and 
mitochondrial matrix, as illustrated in Figure 1-1. The IM contains the subunits 
of the electron transport chain, and is folded into cristae, which increase the 
Figure 1-1. Mitochondrial structure 
Mitochondria have two membranes, the outer membrane (OM) 
and inner membrane (IM). The space between them is known 
as the intermembrane space (IMS), and the matrix is inside the 
IM. The folds in the IM form the highlighted cristae junctions. 
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surface area for oxidative phosphorylation (OXPHOS) to occur (Mannella, 
2006). The mitochondrial matrix contains the mitochondrial DNA, which 
encodes 13 mitochondrial proteins, and 2 ribosomal and 22 transfer RNAs. 
Most mitochondrial proteins are encoded by nuclear genes, synthesized by 
cytoplasmic ribosomes, and then transported and folded into their final 
structures inside mitochondria.  
1.1.2.  Oxidative phosphorylation 
Mitochondria have been called the “powerhouses of the cell” because 
one of their major functions is the production of cellular energy in the form of 
adenosine triphosphate (ATP). OXPHOS is the aerobic process that generates 
ATP in eukaryotic mitochondria via the respiratory chain (RC) complexes (CI-
Figure 1-2. Respiratory chain 
Electrons are transferred (green arrows) from NADH-Q-oxidoreductase (CI) 
and succinate-Q reductase (CII) to coenzyme Q (Q, or ubiquinione), which 
carries the electrons to Q-cytochrome c-oxidoreductase (CIII).  Cytochrome c 
transfers electrons to cytochrome c oxidase (CIV), what catalyzes the 
reduction of O2. Complexes I, III, and IV, pump protons into the 
intermembrane space (IMS), which creates an electrochemical proton gradient 
and drives ATP synthesis through ATP synthase (CV). 
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CIV) and the ATPase complex (CV). In eukaryotes, reduced electron carriers 
that are generated by the tricarboxylic acid cycle enter the RC. In a series of 
redox reactions, electrons are transferred from one RC complex to the next, 
and ultimately donated to molecular oxygen at complex IV to produce water. 
As a consequence of this electron transfer, protons are pumped from the 
matrix to the IMS. This generates an electrochemical gradient, and a proton-
motive force, which is used to drive protons back into the matrix through CV, 
resulting in ATP generation from adenosine diphosphate (ADP) and inorganic 
phosphate. This process is illustrated in Figure 1-2. The ATP that is formed is 
transported across the mitochondrial IM by the adenine nucleotide translocator 
and through the OM into the cytosol. 
1.1.3.  Mitochondrial calcium handling 
Mitochondria also play an important role in ion homeostasis. 
Mitochondrial calcium uptake buffers cytosolic calcium, and plays an important 
role in regulating bioenergetics, as several dehydrogenases in the 
mitochondrial matrix are regulated by calcium (McCormack et al., 1990). 
Mitochondrial calcium handling, illustrated in Figure 1-3, is a tightly regulated 
process involving many proteins, and varies greatly among tissues (Pizzo et 
al., 2012). Calcium enters the mitochondrial matrix through a mitochondrial 
calcium uniporter (Perocchi et al., 2010; Baughman et al., 2011; De Stefani et 
al., 2011), in a process modulated by several regulatory proteins, such as 
MICUs and EMRE (Perocchi et al., 2010; De Stefani et al., 2015; Kamer and 
Mootha, 2015). Calcium uptake requires the mitochondrial membrane potential 
(m) that is generated across the IM. Most of the calcium that enters  
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Figure 1-3. Mitochondrial calcium handling 
A. In normal conditions, calcium enters mitochondria through the 
mitochondrial calcium uniporter (MCU), in the mitochondrial inner 
membrane (MIM). In the matrix, it forms precipitate and activates 
catabolic enzymes, which feed into the respiratory chain (RC). Calcium 
is slowly released via ion exchangers (Ex) in the MIM. B. Once calcium 
accumulation reaches a tissue-dependent threshold, it triggers 
cyclophilin D (CypD) translocation to the MIM and activates the opening 
of the permeability transition pore (PTP), allowing unregulated flow of 
calcium and small molecules.  
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precipitates in the matrix as calcium-phosphate (Kristian et al., 2007), keeping 
the concentration of free calcium fairly low. Free calcium is slowly released  
from mitochondria in excitable cells, such as neurons, via the Na+/Ca2+ 
exchanger, or NCLX, in the IM (Palty et al., 2010). In other tissues, such as 
liver, the Ca2+/H+ exchanger is responsible for mitochondrial calcium extrusion 
(Jiang et al., 2009). When mitochondria are challenged with high calcium, 
mitochondrial permeability transition (MPT) occurs, resulting in swelling, OM 
rupture, and release of pro-apoptotic factors (Crompton et al., 1999; Hansson 
et al., 2011). MPT is the opening of a non-selective pore in the IM that results 
in unregulated flow of solutes and influx of water into the mitochondrial matrix. 
Calcium entry into mitochondria is a classic cause of MPT induction, however, 
MPT can also be induced by inorganic phosphate, oxidizing agents, reactive 
oxygen species, uncouplers, and other agents (Zoratti and Szabo, 1995). 
  
1.2.  Role of mitochondria in brain diseases 
The brain has high energy demands, and relies on ion gradients and 
cellular signaling for neurotransmission (Attwell and Laughlin, 2001). 
Furthermore, the processes required to maintain calcium homeostasis in 
neurons are energetically costly (McCormack et al., 1990; Ivannikov et al., 
2010). Given the critical role of mitochondria in these processes, it is not 
surprising that mitochondrial dysfunction is a key component of brain 
diseases. 
1.2.1.  Mitochondria in neurodegeneration 
Mitochondrial dysfunction is a key component in the pathogenesis of 
neurodegenerative diseases. Many of these diseases develop in late 
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adulthood, and as reviewed in (Lin and Beal, 2006; Sun et al., 2016), a decline 
in mitochondrial function, increased mitochondrial DNA mutations, and 
elevated net reactive oxygen species production are associated with normal 
aging. Furthermore, many mutations in familial neurodegenerative diseases 
are in proteins with key mitochondrial involvement.  
Many of the genes associated with familial Parkinson’s Disease (PD), 
such as Parkin, Pink1 and DJ-1, are associated with mitochondrial quality 
control, oxidative stress and apoptosis. Use of the neurotoxin 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP), induces a Parkinsonian syndrome 
and severe cell loss in the substantia nigra (Langston et al., 1983). This drug 
has been shown to decrease RC complex I activity, and RC complex I defects 
are also found in PD patients (Schapira et al., 1990). 
Mitochondrial dysfunction also plays a role in Amyotrophic Lateral 
Sclerosis (ALS). Postmortem sporadic and familial ALS samples show defects 
in mitochondrial structure and function. Mutations in superoxide dismutase 1 
(SOD1) were the first described in familial ALS, and are among the most 
common (Rosen et al., 1993). Animal models that overexpress the mutant 
human protein develop a disease phenotype, and have been used to 
demonstrate that mitochondrial energy production, calcium loading, and 
overall structure are impaired prior to neuronal death and disease onset (Kong 
and Xu, 1998; Mattiazzi et al., 2002; Damiano et al., 2006). Furthermore, while 
SOD1 is normally localized mainly in the cytosol, mutant SOD1 accumulates in 
mitochondria (Liu et al., 2004; Pasinelli et al., 2004; Vijayvergiya et al., 2005; 
Igoudjil et al., 2011).  
Mitochondria are also connected to many other neurodegenerative 
diseases. In Alzheimer’s Disease (AD), oxidative stress occurs early in 
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disease progression (Nunomura et al., 2001), and many implicated proteins 
such as Aβ and γ-secretase, which are found in the plasma membrane and 
other cellular compartments, also localize to the mitochondria (Hansson et al., 
2004; Manczak et al., 2006). In Huntington’s Disease (HD), defects in energy 
production have been demonstrated, and mitochondrial toxins that target CII 
induce a phenotype similar to HD (Brouillet et al., 1995; Gu et al., 1996).  
1.2.2.  Mitochondria in stroke 
Mitochondria have been implicated in ischemic cell death via their role 
in energy production and in both necrotic and apoptotic cell death pathways. 
Within the ischemic core, the blood flow reduction during the ischemic period 
leads to impaired oxygen delivery and a rapid decline in ATP (Folbergrova et 
al., 1992).  Cells may recover if the ischemic period is short, but if extended 
the major energy deficits in the ischemic core lead to necrosis (Sims and 
Muyderman, 2010). The penumbra, the region surrounding the core, also 
suffers from a rapid reduction in oxidative metabolism during ischemia but to a 
lesser extent. Energy metabolites and respiratory function can be temporarily 
restored briefly upon reperfusion, but a secondary decline occurs later in the 
reperfusion period. It is this later period of decline that is associated with 
massive neuronal death (Lust et al., 2002).  
In addition to the role of mitochondrial energy deficits in stroke 
pathology, other mitochondrial phenomena are involved. The role of MPT was 
established by key studies demonstrating that both inhibition (Korde et al., 
2007) and genetic ablation (Baines et al., 2005; Nakagawa et al., 2005; 
Schinzel et al., 2005) of the major pore regulator cyclophilin D (CypD) reduce 
necrosis following ischemia-reperfusion. Both MPT and the recruitment of pro-
  8   
 
apoptotic Bcl-2 family proteins to the mitochondrial OM are involved in the 
release of apoptogenic factors from mitochondria (Guegan and Sola, 2000; 
Gao et al., 2005). 
 
1.3.  Aims of thesis work 
As summarized above, mitochondria are complex organelles that serve 
many functions, which are critical for cell viability, particularly in tissues with 
high energy demands, such as the brain and heart. Nevertheless, many 
aspects of mitochondrial function are not well understood, and many proteins 
that localize to mitochondria are not well characterized. The work described in 
this thesis aims to elucidate novel functions of two different proteins that are 
found in mitochondria in the central nervous system, and may play a role in 
disease pathogenesis.  
The next chapter of this dissertation is focused on the role of estrogen 
receptor beta (ERβ) in mitochondria. Given the sex differences in stroke, and 
the importance of the MPT, we investigated the role of sex, as well as sex 
hormones and receptors in brain mitochondrial calcium-induced MPT. 
The ERβ studies revealed a novel role in mitochondria for a protein that 
has well-characterized functions in the nucleus. However, the third chapter of 
this thesis is focused on another mitochondrial protein, coiled-coil-helix-coiled-
coil-helix domain containing 10 (CHCHD10), on which no information was 
available at the start of this thesis work. Mutations in the gene encoding 
CHCHD10 were recently associated with ALS and other neuromuscular 
diseases, thus we were interested in uncovering the function of the protein in 
order to understand its role in disease. 
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Taken together, the studies in this dissertation revealed novel functions 
of two mitochondrial proteins, ERβ and CHCHD10, which can help to unravel 
cellular mechanisms underlying the pathogenesis of neurodegenerative 
disease and stroke. 
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2.  ESTROGEN RECEPTOR BETA MODULATES PERMEABILITY 
TRANSITION IN BRAIN MITOCHONDRIA 
 
2.1.  Abstract 
Recent evidence highlights a role for sex and hormonal status in 
regulating cellular responses to ischemic brain injury. A key pathological event 
in ischemic brain injury is the opening of a mitochondrial permeability transition 
pore (MPT) induced by excitotoxic calcium levels, which can trigger 
irreversible damage to mitochondria accompanied by the release of pro-
apoptotic factors. Sex differences in MPT modulation in the brain have not 
been explored. Here, we show that mitochondria isolated from female mouse 
forebrain have a lower calcium threshold for MPT than male mitochondria, and 
that this sex difference depends on the MPT regulator, cyclophilin D (CypD). 
We also demonstrate that an estrogen receptor beta (ERβ) antagonist inhibits 
MPT and genetic ablation of ERβ decreases the sensitivity of mitochondria to 
the CypD inhibitor, cyclosporin A. These results suggest a functional 
relationship between ERβ and CypD in modulating MPT. Co-
immunoprecipitation studies identified several ERβ binding partners in 
mitochondria. Among these, the mitochondrial ATPase was investigated as a 
putative site of regulation. We find that the known interaction between the 
ATPase subunit OSCP and CypD is decreased by ERβ knockout, providing a 
potential molecular mechanism of MPT regulation. Functionally, in a 
hippocampal slice oxygen glucose deprivation model, both CypD inhibition and 
ERβ knockout are protective exclusively in female slices. Taken together, 
these results identify a novel pathway for brain MPT regulation via ERβ that 
could contribute to sex differences in ischemic brain injury outcome. 
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2.2.  Introduction 
2.2.1.  Sex differences in stroke 
There is a growing body of evidence describing sex differences in 
ischemic brain injury. Many factors are thought to contribute to increased 
overall stroke risk and worse stroke outcome in women compared to men, 
including longer average life expectancy, post-menopausal hormonal changes, 
and hormonal replacement therapies (Writing Group et al., 2010). 
Furthermore, recent studies have highlighted cellular mechanisms, which differ 
between males and females, that may contribute to sex differences in stroke 
incidence and recovery (Spychala et al., 2017). For example, females have 
enhanced caspase activation compared to males in animal stroke models (Zhu 
et al., 2006; Liu et al., 2009). Conversely, stroke induced NAD+ depletion and 
caspase-independent nitric oxide and PARP-1 activation are prominent in 
males and ovariectomized females, but not in intact females (Siegel and 
McCullough, 2013). There are also more prominent increases in stroke-
induced autophagy in females compared to males (Chen et al., 2013; Weis et 
al., 2014). While there have been some studies of sex differences in 
mitochondrial function in response to glutamate toxicity and oxidative stress 
(Chauhan et al., 2017), it is clear that further studies comparing sexes are 
needed to improve our understanding of the role of mitochondria in sex 
differences in stroke-induced cell death.  
2.2.2.  Mitochondrial permeability transition 
One important cellular phenomenon in ischemic brain injury is 
mitochondrial permeability transition (MPT) (Starkov et al., 2004; Racay et al., 
2009). MPT is the opening of a non-selective pore in the IM that results in 
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unregulated flow of solutes and influx of water into the mitochondrial matrix. 
MPT results in swelling of mitochondria, OM rupture, and release of pro-
apoptotic factors (Crompton et al., 1999; Hansson et al., 2011). A key trigger 
for MPT pore opening is a high level of calcium in the mitochondrial matrix. 
Calcium enters mitochondria through the mitochondrial calcium uniporter 
(MCU) using m as a driving force (De Stefani et al., 2011). A moderate 
calcium influx in mitochondria is critical for activation of matrix 
dehydrogenases of the TCA cycle, and boosts oxidative metabolism 
(McCormack et al., 1990). However, at high calcium concentrations, such as in 
ischemia reperfusion when neurons are flooded with calcium due to the 
opening of plasma membrane channels and release from internal calcium 
stores (Tymianski et al., 1993; Peng and Greenamyre, 1998), MPT occurs 
(Gouriou et al., 2011). It is important to note that alternatively to irreversible, 
damaging MPT, reversible and transient MPT can lead to opening of a low-
conductance pore that may serve as a protective calcium extrusion 
mechanism (Bernardi and von Stockum, 2012). 
The precise composition and mechanisms of regulation of the MPT 
pore remain controversial, although several candidates for structural and 
modulatory proteins have been proposed (reviewed in: (Bernardi and Di Lisa, 
2015; Halestrap and Richardson, 2015)). Nevertheless, it is widely accepted 
that a key MPT modulatory protein is CypD, a matrix protein, which upon 
calcium influx translocates to the mitochondrial IM to promote MPT opening 
(Bernardi et al., 1994; Connern and Halestrap, 1994). In the absence of CypD 
(Basso et al., 2005; Schinzel et al., 2005) or under its pharmacological 
inhibition (Broekemeier et al., 1989; Szabo and Zoratti, 1991), MPT can still 
occur, but the calcium threshold for its activation is much higher. 
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Although sex differences in MPT have been observed in heart (Arieli et 
al., 2004; Milerova et al., 2016), the molecular mechanisms underlying these 
differences are unknown. Furthermore, whether males and females differ in 
brain MPT has not been explored. 
2.2.3.  Estrogen and estrogen receptors (ERs) in mitochondria 
Sex hormones are clear potential candidates for modulators of 
mitochondrial functions. It is known that estrogens affect intracellular calcium 
dynamics (Zhao and Brinton, 2007; Zhang et al., 2010) and mitochondrial 
function (Nilsen et al., 2006), in both receptor dependent and independent 
manners (Simpkins et al., 2010). Two estrogen receptors, alpha (ERα) and 
beta (ERβ), were originally identified as nuclear receptors (Greene et al., 
1986; Tremblay et al., 1997). Subsequently, both receptors have been shown 
to also localize to mitochondria (Chen et al., 2004), although for ERβ this has 
been more thoroughly characterized (Yang et al., 2004; Milner et al., 2005). 
Both male and female mouse brain contain ERβ in many regions, and some 
areas have more ERβ-containing cell profiles in females than in males (Milner 
et al., 2010), which may contribute to sex differences in MPT. However, 
despite the known effects of estrogen on mitochondrial function and the 
finding of ERs in mitochondria, until now the role of estrogen receptors in sex 
differences in MPT regulation has not been explored.  
In this study, we investigated sex differences in calcium-induced MPT in 
mouse brain mitochondria, the mechanisms of ERβ and CypD MPT 
modulation, and the potential involvement of such mechanisms in ischemia 
reperfusion injury.  
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2.3.  Materials and methods 
2.3.1.  Animals 
CypDKO mice in the C57Bl/6J background have been described 
previously (Schinzel et al., 2005). CypDKO homozygotes are born at 
Mendelian frequency, do not display gross abnormal phenotypes, and are 
protected compared to controls in ischemia reperfusion injury (Schinzel et al., 
2005). ERβKO mice in the C57Bl/6J background were from The Jackson 
Laboratories (strain B6.129P2-Esr2tm1Unc/J). ERβKO homozygotes are born at 
Mendelian frequency, are normal in size, and do not have gross phenotypic 
abnormalities, though homozygote females are sub-fertile (Krege et al., 1998). 
CypDKO and ERβKO were crossed to obtain ERβ/CypD double KO animals. 
Heterozygote males and females were bred to obtain homozygote double KO 
animals. We performed all breeding and genotyping for these experiments at 
Weill Cornell Medicine. Adult animals (130 days of age) were used to isolate 
brain mitochondria for the calcium capacity and m measurements, and 
postnatal day 5 animals were used for the organotypic hippocampal slice 
cultures. 
All experiments were approved by the Institutional Animal Care and 
Use Committee of the Weill Cornell Medicine and carried out in compliance 
with the National Institute of Health guidelines for the care and use of 
laboratory animals. 
2.3.2.  Preparation of mitochondria from brain 
Purification of mouse forebrain non-synaptic mitochondria was 
performed as described in previous publications from our laboratory (Damiano 
et al., 2006; Kim et al., 2012). Mice were euthanized by decapitation, and the 
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forebrain removed and homogenized using a glass Dounce homogenizer on 
ice in ice-cold MS-EGTA buffer (225 mM mannitol, 75 mM sucrose, 5 mM 
HEPES, 1 mM EGTA, pH 7.4) containing 0.1 mg/ml fatty acid-free bovine 
serum albumin (BSA). All centrifugation steps were performed using a Type 
70.1 Ti rotor in a Beckman Optima XE-90 centrifuge. The homogenates were 
centrifuged at 2,000 g for 5 minutes; the supernatant was collected and 
centrifuged at 12,000 g for 10 minutes. The pellet was suspended in 1 mL MS-
EGTA (without BSA), layered on top of isolation buffer containing 23% Percoll. 
The gradient was centrifuged at 40,000 g for 12 minutes and then the 
interphase layer containing mitochondria was collected. The mitochondria 
were suspended in isolation buffer and centrifuged at 12,000 g for 10 minutes, 
three times. The pellet containing purified mitochondria was resuspended in 
MS-EGTA and protein concentration was calculated using a BCA assay kit 
(Pierce). 
2.3.3.  Calcium capacity and membrane potential measurements 
Mitochondria (0.1 mg protein/mL) were subjected to 25 μM pulses of 
calcium every 150 seconds in the spectrofluorimeter cuvette in the presence of 
125 mM KCl, 20 mM HEPES, 1 mM MgCl2 (pH 7.2), 4 mM KH2PO4, 0.2 mM 
ATP, 1 μM rotenone and 5 mM succinate. Fura-FF (0.2 μM, Life Technologies) 
was used to measure calcium uptake using 340/380 nm excitation and 510 nm 
emission. A final addition of EGTA (1 mM) was added. Fluorescence traces 
over time were obtained and calcium capacity, the point at which mitochondria 
start to lose the ability to take up all of the calcium in the buffer, was 
calculated. The fluorescence levels measured at 75 seconds after each 
calcium addition were plotted and the inflection point was determined. To 
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correlate the inflection point to a calcium concentration, calcium standards of 
known concentration were added to create a calibration curve and calculate 
mitochondrial calcium capacity (nmol Ca2+/mg protein). In some experiments, 
the CypD inhibitor cyclosporin A (CsA, 1 μM) was added to mitochondria prior 
to the first calcium addition. CsA binds to CypD and inhibits MPT pore 
formation (Broekemeier et al., 1989; Griffiths and Halestrap, 1991). CsA has 
also immunosuppressant and nephrotoxic effects as a result of the inhibition of 
calcineurin (Liu et al., 1991). However, in experiments in isolated mitochondria 
it is frequently used to study calcium-dependent MPT (Broekemeier et al., 
1989). 
Mitochondrial calcium capacity measurements were performed in 
absence or presence of the ERβ inhibitor 4-[2-Phenyl-5,7-
bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol (PHTPP, Tocris 
Bioscience) or the ERα inhibitor 1,3-Bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-
piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride (MPP, Tocris 
Bioscience), added prior to calcium additions. PHTPP is 36-fold selective for 
ERβ in binding, and was fully effective as an ERβ antagonist in a transcription 
based assay, with no effect on ERα (Compton et al., 2004). MPP is a highly 
selective ERα antagonist with >200-fold binding selectivity for ERα over ERβ, 
and demonstrated selectivity in transcription-based assays (Sun et al., 2002).  
Safranin O (2 μM, Sigma) was used to measure m using 495 nM 
excitation and 586 nm emission, in the conditions described above. Following 
sequential calcium boluses, antimycin A (1 μg/mL) was added to inhibit the RC 
and induce maximal depolarization. The percent of maximal depolarization for 
each calcium addition was plotted in order to determine the amount of calcium 
required to induce 50% of the maximal achievable depolarization (Δψm50). To 
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test the ability of mitochondria to generate Δψm, sequential additions of the 
uncoupler SF6847 (2 nM each, Malonoben, Tocris Bioscience) were made, 
and the decrease in Δψm after each addition was plotted.  
Brain mitochondria were isolated and processed in pairs, with careful 
attention paid towards timing of the measurements in relation to mitochondrial 
isolation. Data are presented as mean values and standard error of the mean. 
Differences between two groups were analyzed using Student’s t-test with a 
95% confidence interval.  
2.3.4.  Western blot 
Brain mitochondria samples were prepared in Laemmli buffer with β-
mercaptoethanol, then separated by SDS-PAGE on 12% Tris-acrylamide/bis-
acrylamide gels and transferred to polyvinylidene fluoride membranes 
(BioRad). Membranes were probed overnight with the following primary 
antibodies: anti-Tim23 (BD Transduction Laboratories), anti-mitochondrial 
calcium uniporter (MCU, Sigma), anti-voltage dependent anion channel 
(VDAC, Abcam), anti- mitochondrial calcium uptake 1 (MICU1, Abcam), and 
anti-CypD (Mitoscience). Membranes were incubated with horseradish 
peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch) and 
detected via chemiluminescence. 
2.3.5.  Hippocampal slice culture preparation and oxygen glucose deprivation 
Hippocampal slice cultures (coronal slices, 350μm thick) were prepared 
as previously described (Gahwiler et al., 2001; Zhou et al., 2012a), and 
cultured on Millicell CM membrane inserts (Millipore). After 14 days in culture, 
slices were imaged for three consecutive days after staining with propidium 
iodide (PI) in the culture medium (5 μg/mL). On the first day, baseline PI 
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images were captured (Flbasal) in a transmission fluorescence microscope with 
a 2X objective, and then oxygen glucose deprivation (OGD) was performed. 
Briefly, slices were washed in OGD buffer (125 mM NaCl, 5 mM KCl, 1.2 mM 
Na2PO4, 26 mM NaHCO3, 1.8 mM CaCl2, 0.9 mM MgCl2, 10 mM HEPES, pH 
7.4), and then incubated in OGD buffer without glucose in an anoxic gas 
chamber (Billups-Rothenberg, Inc.) for one hour, and then returned to normal 
culture medium, containing 5 mg/mL glucose. Anoxia was achieved by 
bubbling the OGD buffer without glucose with 95% N2/5% CO2 before the start 
of the OGD, and by flushing the sealed gas chamber with 95% N2/ 5% CO2 
upon starting the OGD. On the second day, post-OGD PI images were 
captured (FlOGD). Then, slices were treated with 1 mM N-Methyl-D-aspartic 
acid (NMDA) for 24 hours. On the third day, post-NMDA PI images were 
captured, representing the maximum death in each slice (Flmax). The same 
imaging settings were used at all time points, and images from the CA1 
hippocampal region were used to calculate the proportion of OGD-induced 
death using the formula (FlOGD – Flbasal)/(Flmax – Flbasal) x 100%. 
2.3.6.  Cell culture, transfection, and FLAG co-immunoprecipitation  
COS-7 cells were cultured in high-glucose (4.5 g/L) Dulbecco’s 
modified Eagle’s medium (DMEM, Life Technologies) supplemented with 5% 
fetal bovine serum (Atlanta Biologicals) and 1% antibiotic-antimycotic (Life 
Technologies). Cells were transfected with the ERβ-Flag construct (Addgene 
#35562) using the Lonza Nucleofector device according to the manufacturer’s 
instructions. Enriched mitochondrial fractions were prepared from transfected 
cells. Briefly, cells were harvested and homogenized in MS-EGTA with BSA, 
and centrifuged at 4°C at 800 g for 5 minutes. Supernatants were centrifuged 
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at 10,000 g for 10 minutes, and pellets washed in BSA-free MS-EGTA buffer 
and then resuspended in MS-EGTA. Protein concentrations were quantified 
using a BCA assay kit (Pierce).  
Co-Immunoprecipitation (Co-IP) experiments were performed on 
mitochondrial fractions using a Co-Immunoprecipitation kit (Pierce). Briefly, 
FLAG antibody (Sigma F1804) or normal mouse IgGs (ThermoFisher) were 
covalently coupled to IP resins. Mitochondria (0.5 mg) were suspended in Co-
IP lysis/wash buffer and incubated with the resins overnight. Proteins were 
eluted in elution buffer and eluates neutralized with Tris-HCl pH 8.5. Western 
blot using FLAG antibody was performed to confirm the presence of ERβ-Flag 
in the Co-IP eluates. Each Co-IP was repeated and representative Western 
blots are shown. 
2.3.7.  Protein extraction, digestion and Tandem Mass Tag (TMT) labeling  
Proteins were denatured in 200 mM triethylammoniumbicarbonate, 7 M 
urea, 2 M thiourea and 0.2% SDS, pH 8.5 for 1 hour. Each sample (2 µg) was 
reduced with 11.9 mM tris(2-carboxyethyl) phosphine for 1 hour at 37°C, 
alkylated with 20 mM iodoacetamide for 1 hour in the dark and quenched with 
20 mM dithiothreitol (DTT). The proteins were precipitated with acetone and 
frozen overnight, reconstituted in 90 µL of 100 mM 
triethylammoniumbicarbonate and digested with 0.2 μg trypsin for 18 hours at 
37°C. The TMT 6-plex labels were reconstituted with 45 µL of anhydrous ACN 
and added to each of the digest samples for 1 hour at room temperature. The 
peptides from the 6 samples were mixed with each tag: 126-tag (mock IP #1), 
127-tag (ERβ-FLAG IP #1), 128-tag (ERβ-FLAG + 17βE #1) 129-tag (mock IP 
#2), 130-tag (ERβ-FLAG IP #2), and 131-tag (ERβ-FLAG + 17βE #2). The six 
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samples were pooled, evaporated to dryness and subjected to cation 
exchange chromatography fractionation using a PolyLC strong cation-
exchange cartridge (PolyLC Inc. Columbia, MD). The pooled peptides were 
then reconstituted with 3 mL of loading buffer (10 mM potassium phosphate 
pH 3.0, 25% ACN), and the pH adjusted to 3.0 with formic acid. After 
conditioning of the strong-cation exchange (SCX) cartridge 
(PolySULFOETHYL A, 10 mm id x 14 mm, particle size 12 µm, pore size 300 
Å), the sample was loaded and washed with an additional 2 mL of loading 
buffer. The peptides were eluted in three isocratic steps by 1 mL of loading 
buffer containing 50 mM, 150 mM and 500 mM KCl for each step. Desalting of 
SCX fractions was carried out using solid phase extraction (SPE) on Sep-Pak 
Cartridges (Waters, Milford, MA) and the eluted peptides were evaporated to 
dryness.  
2.3.8.  Nano-scale reverse phase chromatography and tandem mass 
spectrometry (nanoLC-MS/MS) 
Each fraction was reconstituted in 15 μL 0.5% FA, and nanoLC-ESI-
MS/MS analysis was carried out using an Orbitrap Elite (Thermo-Fisher 
Scientific, San Jose, CA) mass spectrometer equipped with a “CorConneX” 
nano ion source device (CorSolutions LLC, Ithaca, NY). The Orbitrap was 
interfaced with a Dionex UltiMate3000RSLCnano system (Thermo, Sunnyvale, 
CA).  Each sample was injected onto a PepMap 100 C-18 RP nano trap 
column (5 µm, 100 µm  20 mm, Thermo) with nanoViper Fittings at 20 L/min 
flow rate and then separated on a PepMap C-18 RP nano column (3 µm, 75 
µm x 15 cm), and eluted in a 120 min gradient of 5% to 38% acetonitrile (ACN) 
in 0.1% formic acid at 300 nL/min., followed by a 5-min ramping to 95% ACN-
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0.1% FA and a 5-min hold at 95% ACN-0.1% FA. The Orbitrap Elite was 
operated in positive ion mode (nano spray voltage 1.6 kV, source temperature 
at 250°C). The instrument was operated in data-dependent acquisition (DDA) 
mode using FT mass analyzer for one survey MS scan for selecting top 15 
precursor ions followed by data-dependent HCD-MS/MS scans on the 
precursor peptides with multiple charged ions above a threshold ion count of 
8000 with normalized collision energy of 37%.  MS survey scans at a 
resolution of 60,000 (fwhm at m/z 400), for the mass range of m/z 375-1600, 
and MS/MS scans at 15,000 resolution for the mass range, m/z 100-2000. 
Dynamic exclusion parameters were set at repeat count 1, an exclusion list 
size of 500, 50 s exclusion duration with ±10 ppm exclusion mass width. The 
activation time was 0.1 ms for HCD analysis. All data were acquired under 
Xcalibur 2.2 operation software (Thermo-Fisher Scientific).  
All MS and MS/MS raw spectra from TMT experiments were processed 
using Proteome Discoverer 1.4 (PD1.4, Thermo) and the spectra used for 
subsequent database search using Mascot Daemon (version 2.3.02, Matrix 
Science, Boston, MA). The human RefSeq sequence plus 
Chlorocebus_aethiops_plus_flander_virus database containing 37,469 
sequence entries was downloaded on August 28, 2013 from NCBInr and used 
for database searches. The default search settings used for 6-plex TMT 
quantitative processing and protein identification in Mascot server were:  two 
mis-cleavages for full trypsin with fixed carbamidomethyl modification of 
cysteine, fixed 6-plex TMT modifications on lysine and N-terminal amines and 
variable modifications of methionine oxidation, and deamidation on 
asparagines/glutamine residues. The peptide mass tolerance and fragment 
mass tolerance values were 15 ppm and 100 mDa. The significant scores at 
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95% confidence interval for the peptides defined by a Mascot probability 
analysis (www.matrixscience.com/help/scoring_ help.html#PBM) greater than 
“identity” were used as filters along with a p value of < 0.05 (expectation 
value).  The resulting peptides are considered to be confidently identified 
peptides with at least 2 unique peptides per protein. Intensities of the reporter 
ions from TMT tags upon fragmentation were used for quantification of 
peptides. 
2.3.9.  OSCP co-immunoprecipitation 
Enriched mitochondrial fractions from HEK293 cells or purified brain 
mitochondria were prepared as described above. The OSCP antibody (Santa 
Cruz #sc-365162) or normal mouse IgGs (ThermoFisher) were coupled to the 
resin provided in the co-immunoprecipitation kit (Pierce) and co-IP of 
mitochondrial preparations (0.5 mg) was performed overnight in the following 
buffer: 50mM Tris-HCl, 150mM NaCl, 1mM EDTA, 0.1% NP-40, pH 7.4 (Beck 
et al., 2016). Proteins were eluted from the resin using the provided buffer and 
samples subjected to Western blot, as described above. 
 
2.4.  Results 
2.4.1.  Sex difference in brain mitochondria calcium capacity depends on 
CypD 
To investigate sex differences in calcium-induced MPT we used 
mitochondria freshly isolated from adult mouse forebrain (130 days of age). 
Mitochondria were prepared via centrifugation of forebrain homogenates in a 
Percoll gradient. Calcium capacity, defined as the maximal amount of calcium 
that mitochondria could take up before undergoing MPT, was measured with a 
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fluorimetric approach. Mitochondria were resuspended in buffer containing 
respiratory substrates and the ratiometric calcium probe Fura-FF, and 
sequential calcium boluses (25 μM each) were added to the cuvette.  
Mitochondrial calcium uptake was indicated by a deflection in the 
fluorescence ratio trace. The calcium concentration was increased until uptake 
was no longer observed, indicating MPT. Representative traces of calcium 
uptake show that female brain mitochondria (gray trace) take fewer calcium 
additions than males (black trace), before undergoing calcium-induced MPT 
(Figure 2-1 A). Calcium capacity was calculated by correlating the inflection 
point of the fluorescence ratio trace to a standard curve obtained with calcium 
standards. The quantification of MPT threshold demonstrated that calcium 
capacity was significantly lower in female mitochondria compared to male 
mitochondria (p=0.012, n=8, Figure 2-1 B). 
Figure 2-1. Sex difference in brain mitochondrial calcium capacity 
A. Representative fluorimetric traces of calcium uptake in mitochondria 
purified from male (black line) and female (gray line) adult (130 days of 
age) mouse mouse forebrain. B. Quantification of brain mitochondrial 
calcium capacity in wild type males and females. n = 8 animals per group; 
* p<0.05. 
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In order to understand the mechanism underlying the sex difference in 
brain mitochondrial calcium capacity MPT, we investigated the involvement of 
the well-known pore regulator CypD. The classical CypD inhibitor cyclosporin 
A (CsA, 1 μM), added to the cuvette immediately prior to the start of the 
Figure 2-2. Sex difference is cyclophilin D dependent 
A. Representative fluorimetric traces of calcium uptake in the presence of 
CsA (1 μM) in mitochondria purified from male (black line) and female (gray 
line) adult mouse forebrain. B. Quantification of calcium capacity in male 
and female brain mitochondria in the presence of CsA. Calcium capacity in 
CsA treated mitochondria shown as percentage of vehicle treated calcium 
capacity (dashed line) in the figure inset. * p<0.05 vs. untreated; n = 4 
animals per group. C. Representative fluorimetric traces of calcium uptake in 
mitochondria purified from male (black line) and female (gray line) adult 
CypDKO mouse forebrain. D. Quantification of brain mitochondrial calcium 
capacity in CypDKO mice. n = 8 animals per group.  
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calcium boluses, increased calcium capacity in both male and female brain 
mitochondria (by 91 ± 16 % and 62% ± 6, respectively, n=4, p=0.001 and 
p=0.0085, Fig. 2B inset), and abolished the sex difference (p=0.72, Figure 2-2  
A, B). Importantly, we further established the role of CypD by studying brain 
mitochondrial calcium capacity in males and females with genetic ablation of 
CypD (CypDKO). CypDKO also increased calcium capacity in both male and 
female brain mitochondria, and abolished the sex difference (n=8, p=0.93, 
Figure 2-2 C,D). Taken together, pharmacological and genetic evidence 
indicate that CypD is required for the sex difference in mouse brain 
mitochondrial calcium capacity. 
2.4.2.  ER modulates brain MPT in a CypD-dependent manner 
Because of the sex difference in brain mitochondrial calcium capacity 
and the localization of ERs in brain mitochondria, we examined the possibility 
that selective antagonists of ERβ or ERα modulate brain mitochondrial calcium 
capacity. Mitochondria were treated with 5 M of the ERβ inhibitor PHTPP or 
the ERα inhibitor MPP, prior to calcium additions. Calcium capacity was 
markedly increased by PHTPP treatment to approximately the same extent in 
both male and female brain mitochondria relative to untreated mitochondria 
(respectively by 62% ± 3, p=0.004 and 57% ± 15, p=0.005, n=3, Figure 2-3 A) 
and eliminated the sex difference (p=0.78). This finding was particularly 
interesting, as molecules that increase the calcium threshold for MPT are 
under investigation as a therapeutic strategy to prevent apoptosis induction 
(Argaud et al., 2005; Le Lamer et al., 2014; Martin et al., 2014b; Warne et al., 
2016). Furthermore, because PHTPP affected calcium capacity within minutes 
in purified mitochondria, any transcriptional effects of the drug could virtually 
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be excluded, suggesting that ERβ in mitochondria could act as an MPT 
regulator.  On the other hand, the ER antagonist MPP had no significant 
effects on calcium capacity (respectively, p=0.51 and 0.15, n=4), suggesting 
that ERα in mitochondria is not involved in modulating calcium capacity 
(Figure 2-3 B).  
To further examine the role of ERβ in brain MPT we utilized ERβKO 
mice. Similar to wild type mice, ERβKO brain mitochondria calcium capacity 
was lower in females than in males (p=0.004, n=8, Figure 2-4 A), suggesting 
that ERβ is not required for the sex difference. Nevertheless, addition of 
PHTPP to ERβKO mitochondria failed to increase calcium capacity in males 
and females (respectively, p=0.83 and p=0.51, n=3, Figure 2-4 B), indicating 
that the increase of calcium capacity by PHTPP observed in wild type mice 
(Figure 2-3 A) requires ERβ, and therefore it is not an off-target effect of the 
Figure 2-3. Pharmacological inhibition of estrogen receptors 
A. Quantification of calcium capacity in wild type mitochondria treated with 
the ERβ antagonist PHTPP (5 μM). Data are represented as percent of 
calcium capacity of respective vehicle-treated mitochondria (dashed line). * 
p<0.05 vs. untreated; n = 3. B. Quantification of mitochondrial calcium 
capacity of wild type mitochondria treated with ERα antagonist MPP (5 
μM). Data are represented as percent of calcium capacity of respective 
vehicle-treated mitochondria. n = 4.  
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drug. Unlike the effect of CsA on wild type mitochondria (Figure 2-3 B inset), 
CsA modestly increased calcium capacity in both male and female ERβKO 
mitochondria (Figure 2-4 C), and the effect failed to reach statistical 
significance (respectively, 38% ± 6, p=0.24 and 24% ± 6, p=0.23, n=6). 
Nevertheless, as in wild type mitochondria (Figure 2-2 B), the sex difference in 
mitochondrial calcium capacity was abolished by CsA in ERβKO mice (p=0.41, 
Figure 2-4 C).  
To further explore the functional interaction between ERβ and CypD in 
the handling of mitochondrial calcium, we compared the depolarization of 
mitochondria in response to calcium accumulation in wild type and ERKO 
mice, in the presence or absence of CsA. We used Safranin O to assess 
changes in Δψm (Akerman and Wikstrom, 1976). Specifically, we measured 
the mitochondrial depolarization following sequential bolus calcium additions 
(25 µM each), equivalent to those used for Fura-FF measurements. Since 
mitochondrial calcium uptake uses the force of Δψm, each calcium addition 
followed by uptake results in a decrease of Δψm.  
Ultimately, maximal loss of Δψm occurs when mitochondria undergo 
MPT. Example traces of Safranin O fluorescence upon sequential calcium 
additions for wild type and ERKO mitochondria are shown in figure 2-4 D and 
2-4 E, respectively. In wild type mitochondria, on average CsA doubled the 
amount of calcium required to induce 50% of the maximal achievable 
depolarization (Δψm50, Figure 2-4 F). However, in ERβKO mitochondria CsA 
only increased the amount of calcium required for Δψm50 by 1.5 fold (p=0.02, 
n=6). Lastly, we tested brain mitochondrial calcium capacity in ER/CypD 
double KO female mice compared to CypDKO female mice to assess whether  
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Figure 2-4. ERβKO mitochondria have decreased CsA sensitivity. 
A. Quantification of calcium capacity in male and female ERβKO brain 
mitochondria. * p<0.05; n = 8 animals per group. B. Quantification of 
mitochondrial calcium capacity of ERβKO mitochondria treated with PHTPP (5 
μM). Data are represented as percent of calcium capacity of respective 
vehicle-treated mitochondria (dashed line). n = 3 animals per group. C. 
Quantification of calcium capacity of ERβKO mitochondria treated with CsA (1 
μM). Data are represented as percent of calcium capacity of respective 
vehicle-treated mitochondria. n = 6 animals per group. D. Representative 
trace of Δψm in wild type (WT) brain mitochondria with and without CsA (1 
μM). Sequential calcium additions and final addition of antimycin A (AA) are 
indicated with arrows. E. Representative trace of Δψm in ERβKO brain 
mitochondria with and without CsA treatment. F. Quantification of half-
maximum Δψm in the presence of CsA, normalized by vehicle-treated, in WT 
and ERβKO. * p<0.05 vs. vehicle-treated; # p<0.05; n = 6 animals per group. 
G. Quantification of female brain mitochondrial calcium capacity in CypDKO 
and ERβ/CypDKO, and ERβ/CypDKO treated with CsA. n = 3 animals per 
group. 
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the absence of ER modifies the effect of CypDKO. Calcium capacity was not 
significantly different in the two genotypes (p=0.44, n=3, Fig. 2-4 G).  
Taken together, these data indicate that there is a functional 
relationship between ERβ and CypD in modulating calcium-induced MPT in 
brain, and since ERKO did not affect calcium capacity in CypDKO 
mitochondria, we concluded that that ER was functionally upstream of CypD 
in regulating MPT.  
2.4.3.   ERKO does not affect mitochondrial calcium-related protein 
expression or bioenergetics 
ERβ was first identified as a nuclear receptor that regulates the 
expression of an estrogen-responsive transcriptional program (Mosselman et 
al., 1996; Tremblay et al., 1997). However, here we showed that the ER 
antagonist PHTPP affects mitochondrial calcium capacity within minutes, 
suggesting fast-acting mechanisms by which ERβ modulates MPT. To exclude 
that changes in calcium handling were caused by altered levels of proteins 
involved in calcium fluxes in mitochondria, we compared protein expression in 
wild type and ERβKO brain mitochondria. The levels of calcium handling 
proteins were assessed by Western blot of purified brain mitochondrial 
extracts. The intensities of the immunoreactive bands for the mitochondrial 
calcium uniporter (MCU), voltage-dependent anion channel (VDAC), 
mitochondrial calcium uptake 1 (MICU1), CypD, and integral IM protein Tim23 
used as loading reference, were unchanged in ERβKO mitochondria relative 
to wild type (Figure 2-5 A). Furthermore, no differences were observed in the 
levels of these proteins between sexes.  
  30   
 
Mitochondrial calcium buffering ability is closely tied to Δψm, as calcium 
uptake via the MCU requires Δψm, and saturation of mitochondrial calcium 
uptake leads to loss of Δψm (Nicholls and Crompton, 1980). Thus, we 
determined whether differences in the ability to generate m existed 
between wild type and ERβKO brain mitochondria. To this end, we added 
sequential boluses (2 nM each) of the uncoupler SF6847 to purified brain 
mitochondria, and assessed mitochondrial depolarization upon each addition 
using the Safranin O fluorescence method. Upon addition of the uncoupler, 
Figure 2-5. Western blot and uncoupler titration in ERβKO 
A. Representative Western blot of MCU, VDAC, MICU1, CypD, and 
Tim23 as mitochondrial protein loading control in wild type (WT) and 
ERβKO male and female mouse brain mitochondria. B. Depolarization 
of wild type and ERβKO mitochondria in response to sequential 
additions (2nM each) of uncoupler SF6847. Data are calculated as the 
percentage of the initial membrane potential. n = 4 animals per group. 
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mitochondria attempt to maintain their Δψm by enhancing electron transfer 
and proton pumping in the RC. Therefore, the rate of depolarization can be 
taken as a measure of respiratory competence. Results indicated that wild 
type and ERβKO mitochondria did not differ in their ability to generate Δψm 
(n=4, Figure 2-5 B), because the rate of depolarization in response to SF6847 
was virtually identical in the two genotypes. Together, these data excluded 
that the modulation of brain MPT by ERβ was due to effects on the expression 
of key mitochondrial calcium proteins or changes in mitochondrial 
bioenergetics.  
2.4.4.  ERβKO and CypD inhibition decrease cell death in female hippocampal 
slices exposed to oxygen glucose deprivation 
Since calcium-induced MPT plays a role in ischemic brain injury 
(Starkov et al., 2004; Racay et al., 2009) and sex differences in ischemia-
reperfusion injury have been extensively reported (Recently reviewed in 
(Girijala et al., 2016; Spychala et al., 2017)) we hypothesized that modulation 
of the ERβ-CypD axis of MPT could be involved in the pathogenic process.  
To address this hypothesis, we used organotypic hippocampal slice 
cultures prepared from postnatal day 5 wild type or ERβKO littermates. Slices 
were treated with propidium iodide (PI) to label dead cells, and images were 
captured before and 24 hours after exposure to anoxic and glucose-free buffer 
(oxygen glucose deprivation, OGD). Throughout the OGD, slices were treated 
with either vehicle or CsA (1 μM). After assessing cell death induced by OGD, 
the same slices were treated with NMDA (1 mM) to induce maximal cell death.  
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A representative set of images of hippocampal slices subjected to this 
protocol is shown in Figure 6A. In slices from male mice, neither treatment 
with CsA nor genetic ablation of ERβ had any effect on cell death induced by 
OGD (Figure 2-6 B). However, in females, ERβKO had less OGD-induced cell 
death, when compared to wild type slices. Moreover, CsA treatment was 
protective in wild type female slices, but not in ERKO slices (Figure 2-6 B). 
These data suggest that mechanisms underlying the pathological responses to 
Figure 2-6.Oxygen glucose deprivation in hippocampal slices 
A. Representative images of hippocampal slice cultures stained with 
propidium iodide (PI) (indicating cell death) at baseline, 24 hours post-
oxygen glucose deprivation (OGD), and 24 hours post- treatment with 1 
mM NMDA. Bar = 50 μm. B. Quantification of the percentage of PI 
fluorescence 24 hours post-OGD over the percentage of PI fluorescence 
post-NMDA treatment, with subtraction of fluorescence prior to any 
treatment. n = 24, 41, 5, 27, 32, 22, 27, 24 slices per group over 8 
experiments; * p < 0.05 vs. wild type (WT) female. 
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ischemic injury differ in males and females, and that the mitochondrial ERβ-
CypD axis exerts modulatory effects on cell death only in females. 
2.4.5.  ER interacts with mitochondrial proteins in an estrogen-dependent 
manner 
To begin investigating the mechanism of ER modulation on MPT we 
designed a cell-based system to identify ER binding partners in mitochondria 
using an unbiased approach based on co-immunoprecipitation (co-IP) and 
protein mass spectrometry (MS). Since the specificity of commercially 
available antibodies against ERβ is highly controversial (Snyder et al., 2010), 
we used a recombinant FLAG-tagged human ER DNA construct to express 
the full-length, 59 kDa protein (ERβ-FLAG) in COS-7 cells. COS-7 cells were 
utilized for this experiment, because they are efficiently transfected, allow for 
high expression of the transgene due to episomal replication of plasmids, and 
divide rapidly (18 hours), providing large number of cells for mitochondria 
isolation. Western blot using anti-FLAG antibody allowed for both the detection 
and the IP of the expressed protein. The recombinant ERβ-FLAG protein was 
detected in whole cell homogenates, as well as in the cytosolic and enriched 
mitochondrial fractions, confirming that the protein localizes to multiple cellular 
compartments, including mitochondria.  
To address the role of the ERβ ligand estrogen in regulating its 
interactions with mitochondrial proteins, COS-7 cells were transfected with 
ERβ-FLAG and enriched mitochondria fractions were extracted 48 hours after 
transfection. Mitochondria were incubated with estrogen (17βE, 10 M) or 
vehicle for 10 minutes and throughout all steps of protein co-IP. A FLAG 
antibody covalently bound to resins was used to co-IP proteins. As negative 
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control, cells mock transfected with empty plasmid were used. Finally, proteins 
were eluted and subjected to MS. Two independent experiments were 
conducted and only proteins that were detected and identified with high 
confidence (95%) were considered. Among these, we selected only proteins 
known to reside in mitochondria, which were >2 fold enriched in ERβ 
expressing cells treated with 17βE relative to mock and were not enriched in 
cells treated with vehicle. MS of proteins that Co-IP with ERβ identified a 
relatively small number of peptides that fulfilled the enrichment criteria 
described above (Table 1).  
 
Table 1. Peptides identified by mass spectrometry of proteins eluted after Co-
IP with ERβ-FLAG.  
Numbers indicate the ratio of the abundance of the peptides enriched in FLAG 
Co-IP in either the presence or the absence of 17βE, normalized by the 
peptide abundance in the Co-IP eluate from mock transfected cells. 
 FLAG Co-IP + 17βE / 
mock 
FLAG Co- IP / 
mock 
HADHB (mito trifunctional 
protein) 
3.9 0.9 
Calmodulin 2 3.1 0.8 
Hsp10 2.5 0.9 
Ribsomal protein L34 3.3 1.1 
Ribosomal protein L30 6.9 1.1 
Ribosomal protein L35 5.2 0.9 
Ribsomal protein L13 7.4 0.9 
Ribosomal protein S10 5.1 0.8 
ATPase subunit α (F1) 2.6 0.9 
ATPase subunit c (F0) 3.3 0.9 
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One of them was the trifunctional protein b (HADHB), an enzyme that 
catalyzes three steps of β-oxidation and interacts with complex I of the RC in 
the IM. Calmodulin, hsp10, and several of the mitochondrial ribosome protein 
components were also identified among ERβ interactors in mitochondria. In 
addition, the co-IP revealed subunit c of the F0 ATPase and subunit  of the F1 
ATPase as ERβ binding partners, which was particularly intriguing because 
ATPase was previously identified as an ERβ binding partner in rat brain 
(Alvarez-Delgado et al., 2010). Furthermore, both the β subunit (Giorgio et al., 
2013) and the c ring (Alavian et al., 2014) of the ATPase were proposed to be 
structural components of the MPT pore, and the ATPase complex was found 
to be a binding partner of CypD (Giorgio et al., 2009; Chinopoulos et al., 
2011). 
Since it was shown that CypD binds the ATPase complex at the level of 
the oligomycin sensitivity conferring protein (OSCP) in the lateral stalk of the 
complex (Giorgio et al., 2009; Beck et al., 2016), we investigated whether 
ERβ-FLAG could bind directly to OSCP. We transfected HEK293 cells with 
ERβ-FLAG or empty vector (pcdna) and treated them with either vehicle 
(ethanol) or 10M 17E for 24 hours. The presence of ERβ-FLAG in the 
mitochondrial fractions was confirmed by Western blot (Figure 2-7 A, left 
panel). Samples were subjected to co-immunoprecipitation using an antibody 
against OSCP or an IgG control and eluates were probed for OSCP, FLAG 
and CypD. OSCP was successfully pulled down in all samples (Figure 2-7 A, 
right panel), but we did not detect ERβ-FLAG interacting with OSCP. This 
result was in agreement with the ERβ-FLAG co-IP mass spectrometry data, as 
OSCP was not identified. Although a small amount of CypD was found in the 
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IgG co-IP, indicating non-specific binding, it was clearly enriched in the OSCP 
co-IP, confirming previous observations (Giorgio et al., 2009; Beck et al., 
2016).  
Therefore, we tested the hypothesis that in mouse brain ER could 
modulate the interaction between OSCP and CypD. We performed co-IP of 
OSCP in purified brain mitochondria from wild type and ERβKO male and 
female mice. Western blot indicated that expression of OSCP and CypD did 
not differ among samples (Figure 2-7 B, left panel). Interestingly, co-IP of 
OSCP in these samples revealed that the interaction between OSCP and 
Figure 2-7. Protein-protein interactions 
A. Left: Western blot of FLAG, OSCP and CypD in enriched mitochondrial 
fractions from HEK293 cells expressing empty vector (pcdna) or ERβ-
FLAG, with and without 17βE treatment. Right: Western blot of co-IP 
eluate from IgG IP or OSCP co-IP. B. Left: Western blot of OSCP and 
CypD in purified brain mitochondria from wild type (WT) and ERβKO 
males and females. Right: Western blot of co-IP eluate from IgG IP or 
OSCP co-IP. 
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CypD was greatly reduced in male and female ERβKO mitochondria, to levels 
comparable to the non-specific IgG control (Figure 2-7 B).  
 
2.5.   Discussion 
We have identified a novel pathway for MPT modulation in brain that 
can contribute to sex differences in ischemic brain injury. We first 
demonstrated a sex difference in brain mitochondrial calcium capacity 
whereby female brain mitochondria undergo MPT at a lower calcium 
concentration than male mitochondria. Decreased mitochondrial calcium 
capacity reflects an increased propensity for calcium-dependent MPT pore 
opening. The consequences of increased MPT sensitivity depend on the 
properties of the pore opening. MPT may represent an irreversible 
permeabilization event resulting in mitochondrial swelling and release of 
solutes, including calcium and pro-apoptotic factors (Crompton et al., 1999; 
Hansson et al., 2011) or it could be a reversible, limited permeabilization event 
that can facilitate calcium release from the mitochondrial matrix and prevent 
calcium overload (Bernardi and von Stockum, 2012). Previous studies in rat 
heart show that female mitochondria are more resistant to calcium-induced 
swelling following a single calcium bolus than male mitochondria (Milerova et 
al., 2016), and have improved recovery from calcium-induced depolarization 
(Arieli et al., 2004). Furthermore, in heart mitochondrial calcium overload is a 
key cellular event following ischemia reperfusion, which profoundly affects the 
outcome of ischemia (Halestrap and Richardson, 2015). Taken together, this 
evidence suggests that sex differences in calcium-induced MPT can be linked 
to the differences observed in heart ischemia (Ostadal and Ostadal, 2014).  
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Little is known about the mechanisms of sex differences in ischemic 
brain injury and its potential links to MPT. However, because of the increased 
stroke risk in females, particularly in early menopause (Writing Group et al., 
2010), it is possible that sex hormones and their receptors play a role in 
influencing stroke incidence by modulating brain MPT. Therefore, it could be 
hypothesized that decreased calcium capacity in female brain mitochondria is 
involved in increased susceptibility to stroke. On the other hand, a protective 
reversible MPT cannot be completely ruled out, since our experimental 
paradigm with consecutive boluses of calcium is designed to force brain 
mitochondria into irreversible pore opening. Future experiments with different 
conditions will be needed to address this possibility.  
The isolated brain mitochondria used in these studies were prepared by 
a modified version of the original protocols developed by Sims, utilizing a 
Percoll gradient (Sims, 1990; Sims and Anderson, 2008). These mitochondria 
are considered non-synaptic mitochondria derived from post-synaptic neurons 
and glia. Synaptic mitochondria can be generated by Ficoll or Percoll gradients 
combined with digitonin or nitrogen cavitation, and are derived primarily from 
presynaptic terminals (Lai and Clark, 1979; Brown et al., 2004). Synaptic and 
non-synaptic mitochondria differ in morphology (Muller et al., 2005), MPT 
sensitivity to calcium (Brown et al., 2006), CypD content (Naga et al., 2007), 
and overall proteome (Stauch et al., 2014). The methods to prepare synaptic 
mitochondria can disrupt mitochondria and interfere with calcium-induced MPT 
(Brustovetsky et al., 2002), hence non-synaptic mitochondria are more 
frequently used to study MPT and were prepared for our studies. 
Mitochondria-associated ERβ has been identified in both dendrites and 
terminals, though its distribution varies between sub-regions. For example, in 
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some regions such as the hippocampus, only approximately 25% of ERβ 
immunoreactivity is found in axon terminals (Milner et al., 2005). Future work 
exploring the possible role of this ERβ-CypD axis specifically in synaptic 
mitochondria could also be interesting.  
We used pharmacological and genetic approaches to begin to address 
the mechanisms underlying sex differences in brain MPT. We found that both 
inhibition and deletion of CypD eliminated the sex differences in mitochondrial 
calcium capacity, suggesting that CypD is a necessary component of the 
mechanism underlying sex differences. We also demonstrated that the ERβ 
antagonist PHTPP increased mitochondrial calcium capacity and eliminated 
sex differences. These findings were particularly intriguing, because they 
suggested a functional link between ERβ and CypD. Since MPT inhibition has 
been explored as a therapeutic target (Sileikyte and Forte, 2016), but its use 
has been traditionally challenging due to off target effects of CypD inhibition 
(Laupacis et al., 1982), we deemed that this finding could have applications in 
modulating MPT in conditions of brain calcium overload, such as ischemia. 
This led us to further investigate the role of ERβ in MPT. 
We found that ERβ modulated sensitivity to CsA, as the inhibitory effect 
of CsA on MPT in brain mitochondria was attenuated by ERβKO, in both 
males and females. These data further confirmed the functional relationship 
between ERβ and CypD in modulating calcium capacity. However, since sex 
differences persisted in the calcium capacity of ERβKO brain mitochondria, we 
concluded that ERβ could not be the only molecular determinant of the sex 
differences.  
 Similar to our results in brain mitochondria, it was previously shown 
that male and female cardiac mitochondria also contain similar amounts of 
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CypD, VDAC and ATP synthase (Milerova et al., 2016), highlighting a role for 
protein-protein interaction, rather than protein expression levels, as the 
putative mechanism causing a blunted CsA effect in ERβKO brain 
mitochondria. Therefore, using co-IP of mitochondrial proteins with a tagged 
ERβ followed by unbiased MS approach, we searched for candidates for ERβ 
protein interactors in mitochondria. Interestingly, one of the identified proteins, 
HADHB, was previously shown to bind ERβ (Zhou et al., 2012b). Although the 
involvement of HADHB in MPT is still unknown, its location and interactions 
with IM components and ERβ, as well as its effects on cardiolipin (Taylor et 
al., 2012), make it an intriguing candidate for MPT regulation. The list also 
included Calmodulin (Toledo et al., 2014) and hsp10 (He and Lemasters, 
2003), which have been implicated in MPT regulation, although the 
mechanisms of action are not yet known, and further studies will be needed to 
determine how these proteins affect MPT in brain.  
Several of the mitochondrial ribosome protein components were also 
identified. The strong enrichment of the interaction of these proteins with ER 
by estrogen is surprising and the functional meaning unclear, especially in 
relationship to MPT. However, it is possible that ERβ in mitochondria has 
other functions, and the interactions with mitochondrial ribosomal proteins may 
suggest that ER and estrogen are involved in the regulation of mitochondrial 
protein synthesis.  
The co-IP followed by mass spectrometry also revealed subunit c of the 
F0 ATPase and subunit  of the F1 ATPase as ERβ binding partners. This was 
a particularly interesting result for three reasons. First, the ATPase was 
previously identified as an ERβ binding partner in rat brain (Alvarez-Delgado 
et al., 2010). Second, both dimers of the β subunit (Giorgio et al., 2013) and 
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the c ring (Alavian et al., 2014) of the ATPase were proposed to be structural 
components of the MPT pore. Third, the ATPase was found to be a binding 
partner of CypD at the OSCP subunit of the complex (Giorgio et al., 2009; 
Chinopoulos et al., 2011; Beck et al., 2016). We performed co-IP studies using 
OSCP antibody in cultured cells and in brain mitochondria, which did not 
detect a physical interaction between ERβ and OSCP. However, ERβKO 
decreased the binding of OSCP to CypD in brain mitochondria, which could 
explain the decreased sensitivity to CsA in ERβKO mitochondria. Therefore, 
modulation of the interaction between OSCP and CypD could be the 
mechanism of MPT regulation by ERβ in brain mitochondria. Future work will 
take a closer look at these protein-protein interactions and their possible 
modulation by calcium or sex hormones by using genetic and pharmacological 
tools in cell culture models.  
To seek proof of principle that ERβ and CypD play a role in modulating 
the sex differences in the outcome of ischemic injury we used an organotypic 
hippocampal slice culture OGD system. We tested the effects of CsA and 
ERKO using male and female-derived slices, since previous reports showed 
that female-derived cultures were less susceptible to OGD injury than males 
(Li et al., 2005). We found the same baseline susceptibility to hippocampal cell 
death induced by OGD in male and female slices. However, female-derived 
slices were protected by CsA addition or by ERβKO, while male-derived 
cultures were not. This result supports the concept that ERβ and CypD play a 
role in modulating sex differences in ischemia. It also contributes to an 
increasing body of evidence on the role of ERβ in neuronal vulnerability, since 
it was shown that ERβKO is protective under oxidative stress in primary 
neuronal culture models (Yang et al., 2009), and human studies indicate that 
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males and females respond differently to stroke therapies (Dotson and Offner, 
2017; Sohrabji et al., 2017).  
In conclusion, this work identified new molecular players involved in sex 
differences in brain MPT regulation and mitochondrial calcium capacity. 
Importantly, the modulation of brain MPT may also be pathologically relevant 
to other sex biased brain degenerative conditions, in which mitochondrial 
calcium handling is altered, such as ALS (Damiano et al., 2006; Kim et al., 
2012), AD (Supnet and Bezprozvanny, 2010) and PD (Martin et al., 2014a). 
Taken together, these findings suggest that the function of ER in modulating 
MPT could become a therapeutic target in neurodegeneration. 
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3.  FUNCTION OF MITOCHONDRIAL PROTEIN CHCHD10 
 
3.1.  Abstract 
Mutations in CHCHD10 are associated with myopathy, motor neuron 
disease, dementia, and Parkinson’s disease. CHCHD10 is a conserved 
mitochondrial protein with yet unknown function. Here, we investigate 
CHCHD10 properties and the effects of its downregulation in cellular and 
mouse models. CHCHD10 associates with membranes in the mitochondrial 
intermembrane space (IMS) and its mitochondrial localization depends on 
cysteine residues in the twin CX9C domain. Moreover, CHCHD10 interacts 
with a closely related IMS protein, CHCHD2. Both CHCHD10 and CHCHD2 
interact with P32/GC1QR, a protein with various intra and extra-mitochondrial 
functions. CHCHD10 and CHCHD2 have short half-lives, suggestive of 
regulatory rather than structural functions. Acute silencing of CHCHD10 
induces apoptosis in proliferating cultured cells, unrelated to bioenergetic 
defects, which is attenuated by recombinant CHCHD10 or CHCHD2. 
However, upon chronic CHCHD10 silencing, selected cells adapt to survive, 
suggesting that compensatory mechanisms exist. In vivo, CHCHD10 is 
expressed in many mouse tissues, most abundantly in heart, skeletal muscle, 
and liver, and in specific brain regions, notably the substantia nigra. 
Homozygote CHCHD10 knockout mice are born at Mendelian ratio, have no 
gross phenotypes, no mitochondrial bioenergetic defects or mitochondrial 
ultrastructure abnormalities in brain, heart or skeletal muscle, indicating that 
compensatory mechanisms occur in vivo. In summary, we describe novel 
CHCHD10 binding partners and show that while CHCHD10 prevents 
apoptosis, its loss can be compensated for by adaptive mechanisms. Taken 
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together, these results strongly indicate that the process leading to CHCHD10-
linked human diseases are not based on loss of normal function of the protein. 
 
3.2.  Introduction 
3.2.1.  Mutations in CHCHD10 in disease 
 ALS, also known as Lou Gehrig’s disease or motor neuron disease, is a 
rapidly progressing, fatal neurodegenerative disease characterized by loss of 
motor neurons. It is more recently thought that ALS and frontotemporal 
dementia (FTD) are at either end of a disease spectrum termed FTD-ALS, as 
there is overlap of cognitive and motor defects found in both diseases, and 
they are thought to share genetic mutations and pathogenic mechanisms 
(Lattante et al., 2015). About 5-10% of ALS cases are considered familial, 
while the majority are sporadic, meaning that they arise from unknown causes. 
Mutations in many of the genes associated with familial ALS have been 
identified, the most common being C9ORF72 and SOD1. Other disease 
associated mutations are in genes involved in protein degradation, RNA 
processing, trafficking, and several other functions (Robberecht and Philips, 
2013; Therrien et al., 2016).  Complex pathogenic mechanisms are involved in 
both the sporadic and familial forms of FTD-ALS (Peters et al., 2015). One of 
the major pathogenic mechanisms associated with ALS mitochondrial 
dysfunction (Damiano et al., 2006; Magrane et al., 2009; Kawamata and 
Manfredi, 2010; Palomo and Manfredi, 2015; Manfredi and Kawamata, 2016). 
In recent years, several mutations in the gene encoding Coiled-Coil-
Helix-Coiled-Coil-Helix Domain Containing 10 (CHCHD10) have been 
identified in families with ALS or FTD-ALS (Bannwarth et al., 2014; Johnson et 
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al., 2014; Muller et al., 2014; Dols-Icardo et al., 2015; Ronchi et al., 2015; 
Zhang et al., 2015; Perrone et al., 2017). Mutations in this gene have also 
been associated with several other diseases (Pasanen et al., 2016) including 
FTD (Jiao et al., 2016), mitochondrial myopathy (Ajroud-Driss et al., 2015), 
spinal muscular atrophy (Penttila et al., 2015), Charcot-Marie-Tooth disease 
(Auranen et al., 2015), late onset AD (Xiao et al., 2016) and PD (Rubino et al., 
2017). Table 2 lists all reported CHCHD10 mutations associated with disease.  
Table 2. CHCHD10 disease mutations 
Mutation Disease Reference 
Pro12Ser ALS Dols-Icardo, 2015 
Arg15Ser 
(in cis G58R) 
Mitochondrial 
myopathy 
Arjoud-Driss, 2015 
Arg15Leu ALS Müller, 2014; Johnson, 
2014; Zhang, 2015 
His22Tyr FTD Jiao, 2016 
Pro23Thr FTD Zhang, 2015 
Pro23Ser FTD Jiao, 2016 
Ala32Asp FTD Jiao, 2016 
Pro34Ser FTD-ALS, ALS, PD Chaussenot, 2014; Ronchi, 
2015; Chiò, 2015; Perrone, 
2017; Rubino, 2017 
Ala35Asp FTD, Late Onset AD Zhang, 2015; Xiao, 2016 
Val57Glu FTD Jiao, 2016 
Gly58Arg  
 
Mitochondrial 
myopathy 
Arjoud-Driss, 2015 
Ser59Leu Mitochondrial 
myopathy, FTD-ALS 
Bannwarth, 2014; 
Chaussenot, 2014 
Gly66Val ALS, Spinal muscular 
atrophy Jokela type, 
Charcot-Marie-Tooth 
disease type 2 
Müller, 2014; Penttilä, 
2015; Auranen, 2015; 
Pasanen, 2016 
Pro80Leu ALS, FTD-ALS Ronchi, 2015; Zhang, 
2015; Perrone, 2017 
Gln82* FTD Dols-Icardo, 2015 
Pro96Thr FTD-ALS Perrone, 2017 
Gln108* FTD, PD Perrone, 2017 
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CHCHD10 is a 142 amino acid, nuclear-encoded, mitochondrial protein, 
and the first mitochondrial proteins to be associated with familial ALS. 
CHCHD10 is encoded by a highly conserved gene, which contains four exons 
(Figure 3-1 Top). The protein has two predicted domains, a mitochondrial 
targeting signal at the N-terminus, and a coiled-coil-helix-coiled-coil-helix 
domain at the C terminus (Figure 3-1 Bottom). Between these two domains is 
a hydrophobic alpha helix region, lacking a predicted functional or structural 
connotation. Despite ample evidence that mutations in CHCHD10 cause 
diseases in humans, the function of the protein remains unknown. 
  
Figure 3-1. CHCHD10 structure 
Top. CHCHD10 gene consists of 4 exons (grey boxes). Bottom. 
CHCHD10 protein contains a mitochondrial-targeting signal (MTS), a 
coiled-coil-helix-coiled-coil-helix domain (CHCH) separated by a 
hydrophobic amino acid stretch of unknown function. 
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3.2.2.  Twin CX9C proteins 
CHCHD10 contains a twin CX9C domain, which is characterized by two 
pairs of cysteines separated by nine amino acids that fold to form a coiled-coil-
helix-coiled-coil-helix domain. CXnC domains are found in many different 
proteins, and twin CX9C domains are present in several proteins localized in 
mitochondria. In mitochondria, twin CX9C proteins are typically retained in the 
IMS or IM after import through the action of the Mia40-Erv1 disulfide relay 
system, which is illustrated in Figure 3-2 (Hell, 2008; Koehler and Tienson, 
Figure 3-2. Mia40-Erv1 disulfide relay system 
Mitochondrial precursor proteins (green) enter the IMS via the TOM 
complex. In the IMS, they transiently bind to Mia40 via disulfide bonds 
between intramolecular cysteines (red asterisks). This results in the 
release of the CX9C protein in an oxidized folded state, trapping it in the 
IMS. In this process, Mia40 is reduced, and it is reoxidized by Erv1, which 
donates its electrons to cytochrome c, feeding into the RC at cytochrome 
c oxidase (COX). 
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2009). The IMS was thought to be a reducing environment not conducive to 
disulfide bond formation, however, the discovery of Mia40 led to the 
identification of a protein import pathway that relies on thiol-disulfide exchange 
reactions occurring in the IMS (Stojanovski et al., 2008). Mitochondrial 
compartments contain several proteins that regulate the redox state and allow 
for oxidative protein folding, including thioredoxins and glutaredoxins, and the 
existence of a protein import pathway that relies on disulfide bonding 
highlights the importance of maintaining mitochondrial redox state (Chatzi et 
al., 2016).  
A genome-wide analysis of eukaryotic twin CX9C proteins revealed that 
these proteins have many functions and could be involved in the structural 
organization of molecular scaffolds in mitochondria (Longen et al., 2009; 
Cavallaro, 2010).  Mia40 itself contains a twin CX9C domain, which is thought 
to stabilize the protein in the IMS, where it interacts with newly imported IMS 
proteins (Chacinska et al., 2004). CHCHD1 is a component of the 
mitochondrial ribosome (Koc et al., 2013). The twin CX9C proteins, NDUFS5, 
NDUFB7, and NDUFA8 serve as accessory subunits of RC complex I (Brandt, 
2006; Cavallaro, 2010). Most twin CX9C proteins with described functions are 
RC complex IV (cytochrome c oxidase, COX) assembly factors. For example, 
COX17 is a well-characterized mitochondrial copper chaperone containing a 
twin CX9C domain which supplies copper to COX (Arnesano et al., 2005; 
Banci et al., 2008). The twin CX9C proteins COX19 and CMC1 are also 
involved in copper trafficking to COX (Rigby et al., 2007; Horn et al., 2008; 
Horn et al., 2010). 
The mitochondrial twin CX9C proteins CHCHD3 (Li et al., 2016) and 
CHCHD6 (Ding et al., 2015) are components of the mitochondrial contact site 
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and cristae organizing system (MICOS). Sequence analysis of CHCHD3 and 
CHCHD6 predicts that they arose from a gene duplication event before the 
speciation of Homo sapiens and Mus musculus, and that they serve similar, 
but non-overlapping roles (Cavallaro, 2010). This study also predicated a 
similar gene duplication event for another pair of proteins CHCHD10 and 
CHCHD2, and suggested that these two proteins may have similar non-
overlapping roles.   
The functions of CHCHD10 and CHCHD2 are still in the early stages of 
investigation. Deletion of Mic17, the yeast homolog of CHCHD10 and 
CHCHD2, did not significantly affect mitochondrial respiration or structure 
(Longen et al., 2009).  Until recently, very little has been published on the 
function of human CHCHD10 in mitochondria. One study in patient fibroblasts 
containing the S59L mutation in CHCHD10 suggested that this mutation in 
CHCHD10 altered mitochondrial cristae structure maintenance, because of 
faulty interactions with the major component of MICOS, mitofilin, and with 
CHCHD3 and CHCHD6 (Genin et al., 2016).  
CHCHD2 (also called MNNR1), has several proposed functions, 
including regulating complex IV of the RC via a nuclear and mitochondrial 
localization (Aras et al., 2015), modulating cellular susceptibility to apoptosis 
(Liu et al., 2015), promoting cell migration (Seo et al., 2010; Wei et al., 2015), 
and priming cell differentiation (Zhu et al., 2016). 
  50   
 
The sequence alignment of human proteins CHCHD10, CHCHD2, 
CHCHD3, and CHCHD6 is shown in Figure 3-3. This alignment highlights the 
evidence for the two gene duplications that gave rise to CHCHD3 and 
CHCHD6 or CHCHD2 and CHCHD10, respectively (Cavallaro, 2010). 
CHCHD10 and CHCHD2 are highly homologous (58% identity), while 
CHCHD3 and CHCHD6 are also homologous (35% identity), but there is no 
significant similarity between the two pairs. The only similarity resides in the 
twin CX9C domain near the C terminus. This highlights the importance of 
investigating the functions of CHCHD10 and CHCHD2 in parallel, and 
Figure 3-3. Protein sequence alignment 
Human CHCHD2, CHCHD10, CHCHD3 and CHCHD6 sequences were 
aligned using Protein Blast (NCBI). 
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suggests that their function may not overlap with the MICOS proteins 
CHCHD3 and CHCHD6, as previously suggested (Genin et al., 2016). 
Moreover, mutations in CHCHD2, like in CHCHD10, have been associated 
with familial PD (Ogaki et al., 2015; Shi et al., 2016), suggesting that the 
dysfunction of these two proteins may be involved in the pathways underlying 
neurodegenerative diseases.  
The mitochondrial field has characterized the functions of many twin 
CX9C proteins, but is currently in the very early stages of uncovering the 
function of CHCHD10 and CHCHD2. Here, we explore the physiological role 
of CHCHD10 in vitro and in vivo.  
 
3.3.  Material and Methods 
3.3.1.  Animals 
CHCHD10 knockout animals in the C57Bl/6J background were 
generated using CRISPR/Cas9 technology (Yang et al., 2014) by The Jackson 
Laboratories. Plasmids encoding a signal guide RNA designed to introduce a 
mutation (a single nucleotide insertion of an A residue within exon 2, 
P16fs46ter) in the Chchd10 gene and the cas9 nuclease were introduced into 
the cytoplasm C57BL/6J-derived fertilized eggs with well recognized pronuclei. 
Correctly targeted embryos were transferred to pseudopregnant females. 
Correctly targeted pups were identified by sequencing and PCR and further 
bred to C57BL/6J (Stock No. 000664) to develop the colony. Animals were 
genotyped using the TransnetYX automated genotyping service, which uses a 
TaqMan-based, real-time PCR assay. Heterozygote males and females were 
bred to obtain CHCHD10KO animals and littermate controls, which were born 
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according to Mendelian ratio. Generation of founder mice was performed at 
The Jackson Laboratories, and all subsequent breeding for the described 
experiments was performed at Weill Cornell Medicine. 
All experiments were approved by the Institutional Animal Care and 
Use Committee of the Weill Cornell Medicine and carried out in compliance 
with the National Institute of Health guidelines for the care and use of 
laboratory animals. 
3.3.2.  Cell culture 
HEK293 cells were cultured in high-glucose Dulbecco’s modified 
Eagle’s medium (DMEM, Life Technologies) supplemented with 5% fetal 
bovine serum (Atlanta Biologicals) and 1% antibiotic-antimycotic (Life 
Technologies). To investigate protein turnover in cell culture, HEK293 cells 
were treated with cycloheximide (50 μg/mL, Sigma) in the culture medium. 
Cell number was determined by aspirating culture medium, washing twice with 
PBS to remove floating cells, and by trypsinizing and counting attached cells 
using a Beckman Coulter cell counter. HEK293 cells were selected for these 
experiments, as they are highly transfectable, allow for high expression of the 
transgene, and divide rapidly, providing large number of cells for mitochondria 
isolation.  
Protein lysates or enriched mitochondrial fractions were prepared from 
cells where indicated. To prepare total lysates, cells were harvested in RIPA 
buffer (50 mM Tris-HCl (pH 7.4), 50 mM NaCl, 1% Triton-X, 5 mM EDTA, 10 
mM Na4P2O7, 50 mM NaF) for 30 minutes on ice and then centrifuged 13,000 
rcf for 10 minutes at 4°C to obtain protein supernatants. To prepare the 
enriched mitochondrial fractions, cells were harvested and homogenized in 
  53   
 
mannitol-sucrose buffer (225 mM mannitol, 75 mM sucrose, 5 mM HEPES, 1 
mM EGTA, 1 mg/mL fatty-acid free BSA, pH 7.4), and centrifuged at 4°C at 
800 rcf for 5 minutes. Supernatants were centrifuged at 10,000 rcf for 10 
minutes, and pellets washed in BSA-free mannitol-sucrose buffer and then 
resuspended in mannitol-sucrose buffer. Protein concentrations were 
quantified using a BCA assay kit (Pierce).  
3.3.3.  Co-Immunoprecipitation 
Co-Immunoprecipitation (Co-IP) experiments were performed on 
HEK293 cell mitochondrial fractions using a co-Immunoprecipitation kit 
(Pierce). Briefly, indicated antibody or normal mouse IgGs (ThermoFisher) 
were covalently coupled to IP resins. Mitochondria (0.5 mg) were resuspended 
in Co-IP lysis/wash buffer and incubated with the resins overnight. Proteins 
were eluted in the provided elution buffer and eluates neutralized with Tris-HCl 
pH 8.5. Western blot was performed to confirm the presence of the target 
protein in the Co-IP eluates. Results of Co-IP experiments were reproduced at 
least three times and representative Western blots are shown. 
3.3.4.  Western blot  
Samples were prepared in Laemmli buffer with β-mercaptoethanol, then 
separated by SDS-PAGE on AnyKD Tris-acrylamide/bis-acrylamide gels 
(BioRad) and transferred to polyvinylidene fluoride membranes (BioRad) using 
the Trans Blot Turbo Transfer System. Membranes were probed overnight 
with the following primary antibodies: CHCHD10 (Sigma), CHCHD2 
(Proteintech), OXPHOS subunit cocktail (MitoSciences), P32 (Abcam, used on 
cell lysates), P32 (Cell Signaling, used on mouse tissue), mitofilin (Thermo), 
Tim23 (BD Transduction Laboratories), and β-actin (Sigma). The specificities 
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of the CHCHD10 and CHCHD2 antibodies were confirmed by the absence of 
a band in the immunoblots following siRNA treatment. CHCHD10 antibody 
specificity was also demonstrated in the CHCHD10KO Western blots and 
immunohistochemistry experiments. Membranes were incubated with 
secondary antibodies (anti-mouse or anti-rabbit IgG (H+L), 1:10,000, LiCOR), 
and signal was detected using the Odyssey CLX Imager (LiCOR). 
3.3.5.  Blue native page 
HEK293 were harvested by trypsinization, washed twice with ice cold 
PBS and resuspended in ice-cold PBS (100 μl). To obtain an enriched 
mitochondrial fraction, cells were incubated with 4 mg/ml digitonin (Sigma) in a 
final volume of 200 μl for 10 min on ice. Next, the cells were centrifuged (10 
min, 10,000 g, 4 °C) and mitochondrial pellets were washed twice with 1 ml 
ice-cold PBS. Pellets were solubilized in 100 μl “ACBT buffer” containing 1.5M 
aminocaproic acid (Sigma) and 75 mM Bis-Tris (Sigma). To isolate 
mitochondrial OXPHOS complexes 20 μl 10% (w/v) β-lauryl maltoside (Sigma) 
was added and the solution was incubated for 10 minutes on ice. Following 
centrifugation (30 min, 10,000 g, 4 °C), the protein concentration was 
determined using a protein assay (Pierce) and gels were loaded with 20 μg of 
mitochondrial protein.  
BN-PAGE was performed using a native page TM 4–16% Bis-Tris Gel 
(Invitrogen). Immunodetection was carried out by incubating PVDF 
membranes transferred using the Trans Blot Turbo Transfer System (BioRad), 
with antibodies directed against the NDUFA9 subunit of CI (CI-39; Abcam), the 
70 kDa subunit of CII (CII-70, Invitrogen), the core2 subunit of CIII (CIII-core2; 
Abcam), subunit 2 of CIV (CIV-2; Abcam) and the α subunit of CV (CV-α; 
  55   
 
Abcam). The secondary antibody consisted of IRDye 800CW Conjugated Goat 
Anti-mouse IgG (H+L), Highly Cross Adsorbed (LiCOR, 1:10,000). 
Fluorescence scanning was performed using an Odyssey Imaging system 
(LiCOR) and fluorograms were inverted for visualization purposes.  
3.3.6.  Plasmids, siRNA, and transfection 
CHCHD10 silencing was achieved using three different Silencer Select 
siRNAs from Life Technologies:  s53405 (A, in the 3’ untranslated region), 
s196436 (B, in the 3’ untranslated region), s226550 (C, in coding sequence), 
and the Silencer Select scrambled negative control (#4390846). CHCHD2 
silencing was achieved using two different Silencer Select siRNAs: s224192 
(A, in the 3’ untranslated region), s56012 (B, in the 3’ untranslated region). 
Transient transfection was performed using Lipofectamine RNAiMAX 
(ThermoFisher) according to manufacturer’s instructions. HEK293 cell lines 
with CHCHD10 stable knockdown were created by generating lentiviral 
particles with the Mission shRNA CHCHD10 silencing construct (Sigma, 
SHCLNG-NM_213720) and selecting for transduced clones using puromycin 
(1 μg/mL) in the culture medium. 
 CHCHD10-FLAG (Vigene) and CHCHD2-FLAG (Sino Biological Inc.) 
overexpression plasmids with c-terminal FLAG tags were commercially 
available. The CHCHD10-myc plasmid was generated by mutagenizing the c-
terminus of the FLAG construct to replace the tag (Agilent QuickChange II 
Site-Directed Mutagenesis Kit). Transient transfection and rescue experiments 
using both siRNA and overexpression plasmids were performed using 
Lipofectamine 2000 according to manufacturer’s instructions. Stable cell lines 
with CHCHD10 or CHCHD2 overexpression were generated by transfecting 
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HEK293 cells and selecting for clones using puromycin (1 μg/mL) or G418 
(500 μg/mL) in the culture medium.  
3.3.7.  Protease Protection Assay and Alkaline Extraction  
For the protease protection assay, mitochondria were resuspended in 
10 mM Tris-HCl pH 7, 10 mM KCl, 0.15 mM MgSO4 with 0.25 M sucrose, or 
the same buffer without sucrose in order to cause swelling and produce 
mitoplasts. Mitochondria, mitoplasts, and sonicated mitochondria were treated 
with 0.62 μg/mL proteinase K for 20 minutes on ice and then centrifuged at 
50,000 g for 15 minutes at 4°C.  
For alkaline extraction, mitochondria were first ruptured by sonication. 
Soluble and insoluble fractions were obtained by centrifugation at 50,000 g for 
15 minutes at 4°C. The pellet (insoluble fraction) was resuspended in 0.1 M 
Na2CO3 pH 11, and kept on ice for 30 minutes. The sample was centrifuged at 
the same speed in to separate the membrane associated (supernatant) and 
membrane embedded (pellet) proteins. Protein samples were analyzed by 
Western blot. These experiments were repeated at least three times and 
representative Western blots are shown. 
3.3.8.  Immunocytochemistry 
Coverslips were washed with PBS, fixed in 4% paraformaldehyde for 20 
minutes and washed with 20 mM glycine in PBS (PBS-glycine). Next, cells 
were permeabilized with 0.1% Triton X-100, washed with PBS-glycine, and 
blocked in 0.5% BSA in PBS-glycine. Coverslips were incubated in primary 
antibody for 45 minutes at 37°C, washed in PBS glycine, and incubated in 
secondary antibody (Cy2 or Cy3, Jackson ImmunoResearch) for 45 minutes at 
37°C. Primary antibodies were used for CHCHD10 (Sigma), myc (Abcam), 
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cytochrome c (BioLegend), and Tom20 (SantaCruz FL-145). Coverslips were 
washed with PBS-glycine and mounted using Fluoromount-G 
(SouthernBiotech). 
3.3.9.  Quantification of mitochondrial TMRM accumulation 
TMRM (tetramethyl rhodamine methyl ester) accumulation was used to 
measure m. Microscopy images of HEK293 cells stained with 10 nM 
TMRM (Invitrogen) were acquired using a TCS SP5 Confocal Microscope 
(Leica Microsystems) with an oil-immersion 40 × lens. Cells were washed 
twice and then imaged in HEPES-Tris (HT) imaging buffer (in mM: 132 NaCl, 
4.2 KCl, 1 MgCl2, 5.5 D-glucose, 10 HEPES, 1 CaCl2, pH 7.4 with Tris base) 
at 37°C. The intensity for the region of interest was background corrected 
using a nearby extracellular region of identical size. At the end of the 
experiment, cells were treated with FCCP (1 µM) to determine the lowest 
fluorescence intensity and to prove that the loading of TMRM was comparable 
in different samples.  
3.3.10.  Caspase activity 
Cells were homogenized in lysis buffer (25 mM HEPES pH 7.4, 0.1% 
Triton X-100, 5 mM MgCl2, 2mM DTT, 1.5 mM EDTA, 1X protease inhibitor 
cocktail), incubated on ice for 10 minutes, and centrifuged at 13,000 g for 5 
minutes. The supernatant was mixed with equal volume 2X assay buffer (20 
mM HEPES pH 7.4, 100 mM NaCl, 1 mM EDTA, 0.1% CHAPS, 10% sucrose, 
10 mM DTT), containing ac-DEVD-afc for caspase-3 or Ac-LEHD-afc for 
caspase-9 (each 5 μM, Cayman). Samples were incubated for 1 hour at 37°C 
and read in a plate reader with 405 nm excitation, 505 nm emission 
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wavelengths. Data were expressed as relative fluorescence intensity per mg 
protein (quantified from supernatant). 
3.3.11.  Mitochondrial isolation from tissue 
Isolation and purification of mouse forebrain mitochondria was 
performed using a Percoll gradient as previously described (Damiano et al., 
2006; Kim et al., 2012). The muscle (gastrocnemius) was mashed with 
scissors in a petri dish on ice. The tissue was homogenized with a glass-glass 
homogenizer on ice (30 times loose pestle, 30 times tight pestle) in MS-EGTA 
BSA buffer (210 mM mannitol, 70 mM sucrose, 1 mM EGTA, 5 mM HEPES, 
0.5% fatty acid free BSA). The homogenate was filtered with gauze in order to 
remove fat and fibrous tissue and then was centrifuged at 600 g for 10 minutes 
at 4°C. The supernatant was collected and the pellet was homogenized a 
second time. The combined supernatants were finally centrifuged at 12,000 g 
for 10 minutes at 4°C. Heart mitochondria were prepared by homogenizing 
tissue with a Teflon-glass drill homogenizer on ice for 1 minute in MS-EGTA 
BSA (0.1%) buffer and spinning at 1000 g for 10 minutes at 4°C. The 
supernatant was centrifuged at 8000 g for 10 minutes at 4°C, and pellet 
resuspended in MS-EGTA and centrifuged again. The final mitochondrial 
pellets were resuspended in MS-EGTA without BSA and protein concentration 
was determined using a BCA Assay Kit (Pierce).  
3.3.12.  Measurement of COX activity 
Cytochrome c oxidase (COX) enzymatic activity was measured 
spectrophotometrically (at 550 nm) using a previously described assay in 
isolated mitochondria from tissue or from cells permeabilized with n-dodecyl-
maltoside (Birch-Machin and Turnbull, 2001). Sample was suspended in 
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10mM KH2PO4 (pH 7.4), and reduced cytochrome c (0.025 mM) was added to 
the cuvette. The rate of decrease of absorbance was calculated as nmol 
cytochrome c/min/million cells or mg protein using the extinction coefficient 
E=0.0195 x uM-1 x cm-1. 
3.3.13.  Measurement of oxygen consumption 
HEK293 cells were trypsinized, washed and resuspended in 100 μl of 
MS-EGTA buffer. Part of this suspension (3 μl) was used for protein 
concentration determination and the rest was added to the chamber. O2 
consumption was measured at 37 °C using polarographic oxygen sensors in a 
two-chamber Oxygraph (OROBOROS Instruments, Innsbruck, Austria). After 
the recording of the endogenous respiration in the presence of pyruvate 
(5mM), maximal O2 consumption was determined by adding carbonyl cyanide 
4-(trifluoromethoxy)phenylhydrazone (FCCP, 1 µM). At the end of the 
experiment, potassium cyanide (KCN, 1 mM) was added to completely inhibit 
the respiration.  
Oxygraphic measurements of isolated mitochondria from brain, muscle 
and heart were performed using specific buffers and substrates: pyruvate (5 
mM) and malate (2 mM) in MS-EGTA buffer with 4 mM H2KPO4, 1 mM MgCl2 
for brain; pyruvate (5 mM), malate (2 mM) and glutamate (5 mM) in KCl buffer 
(125 mM KCl, 20 mM HEPES, 4 mM H2KPO4, 1 mM MgCl2, pH 7.2) for 
muscle; malate (2 mM) and glutamate (5 mM) in MS-EGTA buffer with 4 mM 
H2KPO4, 1 mM MgCl2 for heart. Mitochondrial proteins (125 µg) were loaded in 
the chamber in the presence of substrates to determine non-stimulated, State 
2 respiration rate. After addition of 0.5 mM ADP, stimulated State 3 respiration 
rate was assessed. The ATPase inhibitor carboxiactrattilosite (CATR, 1 µM) 
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was then added to inhibit mitochondrial respiration. To determine the maximal 
respiration, 2,4-Dinitrophenol (DNP, 40 µM) was added at the end of the 
experiment. Data analysis was performed using the Oroboros O2k DatLab 
software.  
3.3.14.  Measurement of ATP synthesis 
ATP synthesis in HEK293 digitonin permeabilized cells (1.5 million), or 
mitochondria freshly isolated from tissues (20-60 μg) was measured using a 
rapid kinetic luminescence assay, as described in detail previously (Vives-
Bauza et al., 2007). This assay monitors continuous ATP synthesis using a 
luciferase-luciferase system.  Measurements were performed in buffer 
containing 5mM pyruvate and malate and expressed as nmol ATP/min/million 
cells or nmol ATP/min/mg protein.  
3.3.15.  Calcium capacity measurement 
Calcium capacity was measured fluorimetrically using the ratiometric 
probe Fura-FF.  Methods are described in Chapter 2 in more detail. In these 
studies, calcium capacity in cells was measured in buffer containing 125 mM 
KCl, 20 mM HEPES, 1 mM MgCl2 (pH 7.2), 200 μg/mL fatty-acid free BSA, 4 
mM KH2PO4, 0.2 mM ATP, 1 μM rotenone and 5 mM succinate. In brain, 
mitochondrial calcium capacity was measured using the same buffer and 
substrates described for brain mitochondrial oxygen consumption experiments 
above (with 25 μM EGTA, 200 μg/mL fatty-acid free BSA and 0.2 mM ATP). A 
single 25 μM calcium addition followed by consecutive 10μM additions were 
added to 0.15 mg mitochondria in the presence of Fura-FF (0.2 μM, Life 
Technologies).  
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3.3.16.  Electron microscopy 
Preparation of cell cultures for electron microscopy is described in 
(Cohen-Gould, 2013). Cells were washed with serum-free media or 
appropriate buffer then fixed with a modified Karnovsky's fix of 2.5% 
glutaraldehyde, 4% parafomaldehyde and 0.02% picric acid in 0.1 M sodium 
cacodylate buffer at pH 7.2 (Ito and Karnovsky, 1968). Following a secondary 
fixation in 1% osmium tetroxide, 1.5% potassium ferricyanide (de Bruijn, 
1973), samples were dehydrated through an ethanol series, and embedded in 
situ in LX-112 resin (Ladd Research Industries).  En face ultrathin sections 
were cut using a Diatome diamond knife (Diatome, USA, Hatfield, PA) on a 
Leica Ultracut ultramicrotome (Leica, Vienna, Austria).  Sections were 
collected on copper grids and further contrasted with lead citrate (Venable and 
Coggeshall, 1965). 
Perfusion of animals and fixation of tissue in 3.75% acrolein and 2% 
paraformaldehyde in 0.1M phosphate buffer was performed as described in 
detail in (Milner et al., 2011). Immunohistochemistry was performed on coronal 
brain sections (40 μM thick). Sections were coded by animal using punch 
codes and pooled together to ensure equal treatment throughout the 
procedure. Briefly, sections were incubated in 1% sodium borohydride in 0.1 M 
phosphate buffer, washed in 0.1 M Tris Saline, blocked in 0.5% BSA, and 
incubated in primary antibody in 0.1% BSA while shaking. Next, sections were 
washed and incubated in biotinylated secondary antibody and ABC Solution 
(Vector Laboratories) prior to 3,3’-Diaminobenzidine peroxidase labeling. 
Primary antibodies used in this study were anti-CHCHD10 (rabbit, Sigma) for 
light microscopy, and anti-Tyrosine Hydroxylase (sheep, Millipore) for electron 
microscopy. 
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To prepare tissue sections for electron microscopy, they were fixed with 
2% glutaraldehyde, post-fixed in 2% osmium tetroxide, dehydrated in an 
ethanol series, flat embedded in Embed812 resin (Electron Microscopy 
Sciences, Hatfield, PA), cut (60-70 nm) using a Diatome diamond knife on a 
Leica Ultracut ultramicrotome (Leica Microsystems) and collected on grids. 
Sections were counterstained with uranyl acetate (5% brain, 1.5% muscle and 
heart) and Reynolds lead citrate, and viewed in a Tecnai (FEI) or JEM 1400 
(JEOL, USA, Inc.) transmission electron microscope. 
 
3.4.  Results 
3.4.1.  CHCHD10 is a membrane-associated protein in the mitochondrial 
intermembrane space 
 CHCHD10 localizes to mitochondria, as illustrated by a double label 
immunocytochemistry experiment in HEK293 cells in which CHCHD10 
fluorescence signal completely overlaps with that of the mitochondrial protein 
cytochrome c (Figure 3-4 A). To investigate the submitochondrial localization 
of CHCHD10, a protease protection assay was performed by our collaborators 
at University of Miami. Whole mitochondria, mitoplasts (mitochondria lacking 
the OM), and lysed mitochondria were prepared from HEK293 cells and 
treated with either vehicle or proteinase k to digest exposed proteins. Samples 
were loaded in a Western blot and membranes probed using antibodies 
against CHCHD10 or representative proteins for the mitochondrial IM and 
matrix. Upon protease treatment of whole mitochondria, only OM proteins 
were degraded (Figure 3-4 B). Upon protease treatment of mitoplasts, IM and 
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IMS proteins were digested. Proteins from all mitochondrial compartments 
were digested upon protease treatment of lysed mitochondria. 
CHCHD10 was protected from digestion in whole mitochondria, but not in the 
mitoplast fraction, suggesting it localizes in the IMS or in the outer layer of the 
IM.  
Figure 3-4. Mitochondrial localization of CHCHD10 
A. Immunocytochemistry of HEK293 cells stained with anti-CHCHD10 
(green) and anti-cytochrome c (red) antibodies. Bar = 10 μm. B. 
Western blot of mitochondria (M), mitoplasts (MP) and sonicated 
mitochondria (Sonic) from HEK293 cells in the absence or presence of 
proteinase K (PK). Western blot of control proteins: TIMM50 (inner 
membrane), an HSP60 (matrix). C. Western blot of HEK293 
mitochondria subjected to alkaline extraction using sodium carbonate. 
Western blot of control proteins: LON-P (soluble), COA3 (1 
transmembrane domain), SCO1 (1 transmembrane domain), SDHA 
(loosely bound to membrane) and CMC1 (membrane bound). Total 
(Tot), soluble (S), membrane bound (M, and transmembrane (TM) 
fractions. 
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Next, we subjected mitochondrial fractions from HEK293 cells to  
sodium carbonate treatment followed by a high speed centrifugation to 
separate membrane bound and soluble proteins. Western blot of total 
mitochondrial protein, the soluble protein fraction, membrane associated 
fraction, and integral membrane associated fractions revealed that CHCHD10 
was found in several fractions. While a fraction of the protein was soluble, a 
large portion appeared to be associated with mitochondrial membranes 
(Figure 3-4 C).  
 The twin CX9C protein CHCHD2 is imported via the Mia40-Erv1 
system, as a mutation of any one cysteine in this domain prevents CHCHD2 
mitochondrial localization (Aras et al., 2015). To investigate whether 
CHCHD10 also requires the twin CX9C domain for its mitochondrial 
localization, we generated a plasmid expressing CHCHD10 with a C-terminal 
myc tag (CHCHD10-myc) and a plasmid with a Cys to Ser mutation at position 
Figure 3-5. CHCHD10 cysteine mutagenesis 
Representative images of immunocytochemistry of HEK293 cells 
transfected with WT CHCHD10-myc or C122S CHCHD10-myc. 
Coverslips stained with anti-myc (green) and anti-Tom20 (red) 
antibodies. Bar = 10 μm. 
 
  65   
 
122 (C122S CHCHD10-myc). While CHCHD10-myc colocalized by 
immunostaining with the mitochondrial marker cytochrome c, C122S 
CHCHD10-myc showed a diffuse cytosolic staining, indicating that the Cys at 
position 122 is required for the mitochondrial localization of CHCHD10 (Figure 
3-5). This confirmed that the twin CX9C domain integrity is critical for 
mitochondrial import or retention, presumably by the Mia40-Erv1 system. 
3.4.2.  CHCHD10 and CHCHD2 are homologous binding partners that also 
bind P32 
A previous study suggested that CHCHD10 interacts with mitofilin 
(IMMT), together with CHCHD3 and CHCHD6, in the mitochondrial inner 
membrane cristae organizing system (MICOS) (Genin et al., 2016). We sought 
to reproduce this interaction. We transfected HEK293 cells with a CHCHD10 
construct containing a C-terminal FLAG tag (CHCHD10-FLAG) or empty 
vector, and prepared enriched mitochondrial fractions to be used for co-
immunoprecipitation (Co-IP) of CHCHD10 and associated proteins using a 
Figure 3-6. CHCHD10 and mitofilin do not interact. 
A. Mitochondria from empty vector (mock) or CHCHD10-FLAG transfected 
cells were subjected to Co-IP with FLAG antibody. Western blot of Co-IP 
eluate probed with FLAG and mitofilin antibodies. B. Mitochondria from 
HEK293 cells were subjected to Co-IP with mitofilin antibody or control 
IgG. Western blot of input and Co-IP eluate probed with mitofilin, 
CHCHD10, and Tim23 antibodies. 
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FLAG antibody. The Western blot confirmed the presence of CHCHD10-FLAG 
in the eluate (Figure 3-6 A). However, when we pulled down CHCHD10-FLAG, 
we detected mitofilin in the IP eluate, but mitofilin was also detected in the 
control IgG, indicating non-specific binding of mitofilin to IgGs (Figure 3-6 A). 
Therefore, we performed reverse Co-IP and pulled down mitofilin (Figure 3-6 
B). We did not detect CHCHD10 in the mitofilin Co-IP eluate, but we were able 
to detect Tim23, which was previously shown to interact with mitofilin (Ding et 
al., 2015). Overall, our results indicated that CHCHD10 does not interact with 
mitofilin. Retrospectively, this result was not completely surprising, because 
the CHCHD10 sequence is highly dissimilar to the MICOS proteins CHCHD3 
and CHCHD6 (Figure 3-3). Furthermore, CHCHD10 was not identified in a 
recent study that used crosslinking and mitofilin Co-IP followed by mass 
spectrometry (Janer et al., 2016).  
 Since we were unable to confirm the interactions with mitofilin, to 
search for new potential binding partners of CHCHD10 we used a candidate 
approach. Because CHCHD10 and CHCHD2 are homologous, we explored 
the possibility that they may physically interact. We performed Co-IP using 
mitochondria fractions from HEK293 cells expressing CHCHD10-FLAG and 
detected CHCHD2 in the FLAG Co-IP eluate, but not in the IgG control Co-IP 
indicating that the two proteins interact (Figure 3-7 A). We confirmed this 
interaction by performing the reverse Co-IP, in which cells were transfected 
with CHCHD2-FLAG and Co-IP performed with either FLAG antibody or 
control IgG, and identified CHCHD10 in the FLAG Co-IP eluate (Figure 3-7 B). 
 Next, we investigated whether CHCHD10 could also bind to itself to 
form homo-oligomers. Because of the C-terminal tags in the CHCHD10 
construct, we could distinguish the recombinant CHCHD10 from the 
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endogenous, as it migrates higher in an SDS-PAGE gel. When we performed 
Co-IP of CHCHD10-FLAG using FLAG antibody, we did not detect 
endogenous CHCHD10 in the Co-IP eluate, indicating that CHCHD10-FLAG 
does not bind to endogenous CHCHD10 (Figure 3-7 C). 
CHCHD2 was shown to bind to a protein named P32 (Seo et al., 2010), 
otherwise known as HABP1, C1QBP, and GC1QR. Because of the sequence 
homology and physical interaction between CHCHD10 and CHCHD2, we 
investigated whether CHCHD10 also interacted with P32. We transfected 
HEK293 cells with either CHCHD2-FLAG or CHCHD10-FLAG, prepared 
mitochondrial fractions, and performed Co-IP using a FLAG antibody. We 
confirmed the previously reported interaction between CHCHD2 and P32, and 
Figure 3-7. CHCH1D10, CHCHD2 and P32 Co-IP 
HEK293 cells were transfected with indicated plasmids and enriched 
mitochondrial fractions were prepared (Input). Co-IP with either FLAG 
antibody or control IgGs was performed (IP eluate) and samples were ran in 
Western blot. Membranes were probed with FLAG and additional antibody for 
indicated proteins. 
A. Co-IP, CHCHD10-FLAG transfected cells. B. Co-IP, CHCHD2-FLAG 
transfected cells. C. Empty vector (pcdna) or CHCHD10-FLAG transfected 
cells, each used for Co-IP with FLAG antibody. D. Co-IP, CHCHD2-FLAG or 
CHCHD10-FLAG cells.  
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also detected P32 in the CHCHD10-FLAG Co-IP eluate, but not in the control 
IgG eluate, indicating that P32 and CHCHD10 physically interact in 
mitochondria (Figure 3-7 D). Taken together the Co-IP experiments suggested 
the existence in mitochondria of a protein complex containing CHCHD10, 
CHCHD2, and P32.  
Next, to further characterize the properties of these interacting proteins 
we investigated the turnover of endogenous CHCHD10, CHCHD2, and P32 in 
HEK293 cells. We treated cells with cycloheximide to inhibit protein translation 
for 0.5, 1.5, 3, 6 and 12 hours. Western blot of whole cell homogenates was 
used to examine the turnover of these proteins over time (Figure 3-8 A). We 
observed that CHCHD10 and CHCHD2 levels decreased rapidly (Figure 3-8), 
while P32 and Tim23 (IM CX3C protein) had a much slower decline, 
Figure 3-8. Cycloheximide treatment 
A. HEK293 cells were treated with cycloheximide for indicated number of 
hours and harvested for Western blot using antibodies against CHCHD10, 
CHCHD2, P32 and Tim23 (IM protein). B. Quantification of band intensity 
following, 1.5, 6 or 12 hours of cycloheximide treatment. Data are expressed 
as percentage of the band intensity at 0h for each protein. n = 3 
experiments, 2 samples per time point.  
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suggesting that both CHCHD10 and CHCHD2 are rapidly degraded proteins. 
Moreover, the turnover of CHCHD2 was faster than that of CHCHD10 (Figure 
3-8 B), suggesting that the degradation of these two proteins can be 
differentially regulated, and that CHCHD10 and CHCHD2 can exist 
independently. 
3.4.3.  Transient silencing of CHCHD10 decreases cell number 
Figure 3-9. CHCHD10 siRNA in HEK293 cells 
A. HEK293 cell number in untreated (HEK), or following 24, 48 and 72 hour 
treatment with scrambled or CHCHD10 siRNA. n = 3. B. Western blot of cell 
homogenates and following 24 or 72 hours of treatment with scrambled 
(scram) siRNA or CHCHD10 (siD10) siRNAs. C. Quantification of HEK293 
cell number following 24 or 72 hours siRNA treatment. * p < 0.05 vs. scram, 
n = 3 wells each. 
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To start exploring the function of CHCHD10, we transfected HEK293 
cells with a siRNA against CHCHD10, and noticed a decrease in cell number 
in silenced cells following 72 hours of siRNA treatment(Figure 3-9 A). We 
repeated this experiment with two more unique siRNAs (called B and C), each 
targeting a different region of the CHCHD10 mRNA sequence. All three 
siRNAs caused a rapid and almost complete silencing of CHCHD10 
expression after 24 hours of treatment that persisted at 72 hours, as 
demonstrated by Western blot (Figure 3-9 B). After 24 hours of siRNA 
treatment, no differences in the cell number were observed. However, 72 
hours after silencing, a significant decrease in cell number was observed in 
cells silenced with all three CHCHD10 siRNAs (Figure 3-9 C).  
We also silenced CHCHD2 using two different siRNAs (Figure 3-10 A) 
directed against different regions of the mRNA. After 24 or 72 hours of siRNA 
treatment, we did not observe differences in the number of cells (Figure 3-10 
B). Furthermore, transient simultaneous silencing of both CHCHD2 and  
CHCHD10 (Figure 3-10 C) induced a decrease in cell number similar to that of 
CHCHD10 silencing alone (Figure 3-10 D), suggesting that there were no 
additive effects of co-silencing. 
Next, we investigated whether overexpression of a CHCHD10 or 
CHCHD2 could rescue the loss of cell viability induced by CHCHD10 siRNA 
treatment. We co-transfected HEK293 cells with plasmids (pcDNA empty 
vector, WT CHCHD10-myc or CHCHD2-FLAG) and siRNA (scrambled or 
siD10 A). We chose siD10A because it targets the 3’UTR of the mRNA, which 
is not present in the recombinant CHCHD10-myc construct, and therefore 
does not silence it. Western blot confirmed the expression of the recombinant 
proteins (Figure 3-11 A). After 72 hours, expression of CHCHD10 or CHCHD2 
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constructs had no effect on cell number in cells treated with the scrambled 
siRNA. However, both constructs resulted in a partial rescue of cell number in 
cells treated with CHCHD10 siRNA (Figure 3-11 B). This indicates that, while 
silencing CHCHD2 does not result in loss of cell viability, its expression is able 
Figure 3-10. CHCHD2 siRNA in HEK293 cells 
A. Western blot of cell homogenates and following 24 or 72 hours of 
treatment with scrambled (scram) siRNA or CHCHD2 (siD2) siRNAs. B. 
Quantification of HEK293 cell number. n = 3 wells each. C. CHCHD2 
and CHCHD10 combination silencing Western blot. D. Quantification of 
cell number. * p < 0.05 vs. scram, n = 6 wells each. 
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to cross-complement the effects of CHCHD10 silencing, suggesting that some 
functional overlap exists between CHCHD10 and CHCHD2.  
3.4.4.  CHCHD10 silencing triggers apoptosis. 
To understand the nature of the cell viability loss induced by CHCHD10 
silencing, we examined the mitochondria-dependent apoptosis using a variety 
of approaches.  
The ability to maintain m is usually compromised when cell undergo 
apoptosis (Zamzami et al., 1995) and a decline in m indicates 
mitochondrial dysfunction. Therefore, we examined m using the 
potentiometric probe TMRM at 24, 48, and 72 hours after treatment with 
CHCHD10 siRNA (Figure 3-12 A). Despite effective protein silencing at 24 
hours (Figure 3-9 A) m was maintained (Figure 3-12 A). However, there  
Figure 3-11. Rescue of cell number loss induced by CHCHD10 silencing 
A. Western blot of HEK293 transfected with scrambled or CHCHD10 
siRNA (siD10 A) and empty vector (pcdna), CHCHD10-myc, or CHCHD2-
Flag, overexpression plasmids. B. Quantification of cell number after 72 
hours of treatment with siRNA and/or pcdna, CHCHD10-myc, or CHCHD2-
FLAG overexpression plasmids. * p < 0.05 vs. pcdna + scram, # p < 0.05 
between groups, n = 8 wells each. 
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Figure 3-12. CHCHD10 silencing and apoptosis 
A. Mitochondrial membrane potential measured by average TMRM intensity in 
cells treated with scrambled or CHCHD10 siRNA for 24, 48 or 72 h. Data are 
represented as the percentage of the TMRM intensity of cells treated with 
scram siRNA for 24h. B. Quantification of HeLa cell number after 96h of scram 
or siD10 siRNA treatment. * p < 0.05, n = 3. Immunocytochemistry of 
cytochrome c in HeLa cells after 72h. Arrowheads indicate cells with diffuse 
staining, indicating cytochrome c release from mitochondria into the cytosol. C. 
Caspase 9 activity in cells treated with scrambled or CHCHD10 siRNA for 24, 
48 or 72h. Data are represented as percentage of the cells treated with scram 
siRNA for 24h. # p < 0.05, n = 3 experiments in triplicate. Caspase 9 activity in 
cells treated with scrambled or CHCHD10 siRNA for 24, 48 or 72h. Data are 
represented as percentage of cells treated with scrambled siRNA for 24 hours. 
# p < 0.05, n = 3 experiments in triplicate. D. Electron micrographs of HEK293 
cells 48 or 72h after treatment with scrambled or CHCHD10 siRNAs. Arrows 
indicate mitochondria with abnormal cristae. Bar = 500 nm. 
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was a significant m decrease in silenced cells at 48 hours, which further 
declined at 72 hours (Figure 3-12 A). This indicated that in silenced cells 
mitochondria are unable to maintain normal m in the period preceding the 
time of decline in cell number (i.e., 72 hours).  
We then investigated cytochrome c release from mitochondria by 
immunocytochemistry, as indicated by diffuse cytochrome c staining, which is 
a marker of activation of the mitochondrial apoptotic pathway (Kluck et al., 
1997; Kluck et al., 1999; Goldstein et al., 2000). For this experiment we used 
HeLa cells, which have a larger size and a flatter morphology than HEK293 
cells, which allows for better imaging. HeLa cells treated with scrambled and 
CHCHD10 siRNA also showed a decrease in cell number, although it reached 
statistical significance at 96 hours, slightly later than HEK293 cells (Figure 3-
12 B). Cytochrome c release was detected in HeLa cells after 72 hours of 
CHCHD10 silencing, but not in cells transfected with scrambled siRNA (Figure  
3-12 B), suggesting that the loss of cell number was caused by apoptotic cell 
death.  
To further investigate apoptotic event in CHCHD10 silenced HEK293 
cells, we measured caspase 9 and caspase 3 activities using a fluorimetric 
assay. Both caspase activities were significantly increased 72 hours after  
CHCHD10 silencing compared to scrambled control (Figure 3-12 C), 
confirming the activation of the mitochondrial apoptotic pathway.  
Since mitochondrial apoptosis is usually associated with alterations in 
mitochondrial structure, notably loss of cristae integrity (Scorrano et al., 2002; 
Scorrano, 2009), we studied the mitochondrial cristae structure by electron 
microscopy in cells treated with CHCHD10 siRNA or a scrambled control 
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siRNA. Abnormal mitochondrial ultrastructure, characterized by swelling of the 
matrix space and cristae disruption, was evident in CHCHD10 silenced cells at 
48 and 72 hours (Figure 3-12 D). Taken together, this evidence indicates that 
transient silencing of CHCHD10 triggers a pro-apoptotic cascade, likely 
initiated in mitochondria, which also results in loss of m and mitochondrial 
integrity. 
Since OXPHOS is a critical mitochondrial function and some twin CX9C 
proteins participate in RC complex assembly (Horn et al., 2008; Horn et al., 
2010), we investigated the RC in HEK293 cells upon CHCHD10 silencing. 
Using an antibody cocktail against one subunit of each of the five RC 
complexes, by Western blot we did not detect an effect of CHCHD10 silencing 
on the levels of these subunits after 72 hours of siRNA treatment (Figure 3-13 
A). Furthermore, no differences were found in assembled RC complex levels, 
as assessed by blue native PAGE and Western blot (Figure 3-13 B). 
Functionally, there was a moderate decrease in COX activity (Figure 3-13 C).  
However, this moderate decrease did not result in respiration (Figure 3-13 D) 
in intact cells treated with CHCHD10 siRNA compared to scrambled siRNA, 
nor did it result in ATP synthesis defects, measured by a kinetic luminescence-
based assay in permeabilized cells (Figure 3-13 E). Taken together, these 
results indicate that apoptotic cell death following CHCHD10 transient 
silencing was not directly caused by inability of mitochondria to produce ATP. 
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Figure 3-13. CHCHD10 and OXPHOS complexes in HEK293 cells. 
A. Representative Western blot and quantification of OXPHOS complex 
subunits and Tim23 (mitochondrial loading control) in HEK293 cell 
homogenate after 72h of treatment with scrambled (scram) or CHCHD10 
siRNA (siD10). Data are represented as percentage of scram control. B. 
Representative blue native gel and quantification of OXPHOS complex 
subunits in HEK293 cell homogenate after 72h of treatment with scram or 
siD10 siRNA. Data are represented as percentage of scram control. n = 3 
wells each. C. Cytochrome c oxidase (COX) activity in cells treated for 48h 
with scram or siD10 siRNA. * p < 0.05, n = 6 wells in triplicate. D. Oxygen 
consumption in intact cells treated for 48h with scram or siD10 siRNA. n = 6 
experiments. E. ATP synthesis in permeabilized cells treated for 48h with 
scram or siD10 siRNA. n = 3 wells each in duplicate. 
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3.4.5.  HEK293 cells with stable knockdown of CHCHD10 are viable 
To address the effects of chronic CHCHD10 silencing, we generated 
stable cell lines, in which CHCHD10 was knocked down. HEK293 cells were 
transduced with lentivirus expressing either a CHCHD10 shRNA or a 
scrambled shRNA, and clones were selected in puromycin. All stable clones 
generated showed approximately 80% CHCDH10 silencing (Figure 3-14 A). 
However, no clones with complete CHCHD10 silencing were identified (out of 
8 clones).  Similar to CHCHD10 transient silencing, stable CHCHD10 silencing 
did not affect CHCHD2 and P32 expression levels (Figure 3-14 A). However, 
unlike the transiently silenced cells, the stable CHCHD10 shRNA cell lines 
showed no loss of viability and no growth differences compared to scrambled 
shRNA (Figure 3-13 B). Furthermore, no defects in COX activity (Figure 3-14 
C) or ATP synthesis (Figure 3-14 D) were observed in the stable CHCHD10 
shRNA lines. 
 The CHCHD10 and CHCHD2 binding partner P32 was proposed as a 
MPT pore candidate (Starkov, 2010), Thus, we measured the calcium capacity 
of mitochondria extracted from control and CHCHD10 knockdown HEK293 
stable lines. Calcium capacity was measured fluorimetrically using the 
ratiometric calcium probe Fura-FF. Mitochondria were subjected to repeated  
bolus calcium additions, until they were no longer able to take up the added 
calcium, suggesting the occurrence of MPT. Calcium traces were virtually 
identical in control and knockdown mitochondria (Figure 3-14 E), suggesting 
that CHCHD10 silencing does not affect calcium uptake and calcium-induced 
MPT in HEK293 cells.  
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  Taken together, these results demonstrated that stably silenced 
HEK293 cells can survive with low levels of CHCHD10, and that chronic 
CHCHD10 reduction does not disrupt mitochondrial function. This indicates 
that upon selection cells are able to adapt to CHCHD10 decrease and that this 
Figure 3-14. CHCHD10 stable knockdown HEK293 cell lines 
A. Western blot of CHCHD10, CHCHD2, P32, and β-actin of 
homogenates (50 μg) of 3 cells lines stably expressing scrambled shRNA 
(scram) and 3 cell lines stably expressing CHCHD10 shRNA (siD10). 
Quantification of band intensity normalized by β-actin loading control. B. 
Number of cells 48 hours after seeding either scram or siD10 stable 
HEK293 line. Data are expressed as percentage of scram. n = 3 samples 
each. C. COX activity in scram or siD10 stable line. n = 3 experiments in 
triplicate. D. ATP synthesis in a scram or siD10 stable line measured 
using a luciferase-based assay. n = 3 experiments in duplicate. E. 
Representative Fura-FF calcium capacity traces of scram and siD10 
HEK293 cells with one 25 μM calcium addition and sequential 10 μM 
calcium additions followed by a final addition of 1 mM EGTA. 
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adaptation does not involve compensation by increased expression of 
CHCHD2.  
3.4.6.  CHCHD10 and CHCHD2 in mouse tissue 
 In order to understand the function of CHCHD10 and CHCHD2 in the 
context of an organism, we examined its expression and function in mouse 
tissues. We generated crude mitochondrial fractions from brain, spinal cord, 
heart, lung, liver, kidney, spleen, pancreas and skeletal muscle 
(gastrocnemius) from a wild type adult C57Bl6J mouse, and analyzed 
CHCHD10 and CHCHD2 expression by Western blot (Figure 3-15). CHCHD10 
and CHCHD2 were expressed in all tissues examined, but the levels were 
highest in heart, liver, pancreas and skeletal muscle. Moreover, the patterns of 
tissue expression of CHCHD10 and CHCHD2 were similar, consistent with the 
hypothesis that they participate in a common function. 
Figure 3-15. Western blot of CHCHD10 in mitochondria from mouse 
tissue. 
Representative Western blot using antibodies against CHCHD10, 
CHCHD2, and Tim23 (as mitochondrial loading control), in crude 
mitochondrial extracts prepared from indicated wild type mouse tissues. 
50 μg protein was loaded per sample. SC = spinal cord. 
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 We also investigated the physical interaction between CHCHD10, 
CHCHD2 and P32 in mouse heart, which has high CHCHD10 and CHCHD2 
expression. Mitochondrial proteins from heart were subjected to Co-IP with 
antibodies against CHCHD10, CHCHD2 or control IgG. As in the cell culture 
Co-IP experiment using tagged constructs, we were able to demonstrate 
interactions between endogenous mouse CHCHD10, CHCHD2 and P32 in 
heart (Figure 3-16), suggesting that these interactions occur in vivo and are 
probably involved in the functions of the proteins. Furthermore, we did not 
identify a specific interaction between CHCHD2 or CHCHD10 with mitofilin. 
3.4.7.  CHCHD10 knockout animals are viable and do not exhibit gross 
phenotypic or mitochondrial abnormalities 
Figure 3-16. CHCHD10, CHCHD2, P32 Co-IP in heart 
Mitochondria from mouse heart (Input) were subjected to Co-IP either with 
CHCHD2 antibody, CHCHD10 antibody or control IgGs (IP eluate) and 
samples were run in Western blot. Membranes were probed with CHCHD2, 
CHCHD10, P32, and mitofilin antibodies. 
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We generated a CHCHD10 knockout animal (CHCHD10KO) in 
collaboration with The Jackson Laboratories to investigate the function of 
CHCHD10 in vivo. Using CRISPR/Cas9, we introduced a single adenine 
nucleotide in exon 2 of CHCHD10 (Figure 3-17 A), which resulted in a 
frameshift mutation and premature stop codon. Breeding of heterozygote 
animals resulted in homozygote KO animals born at Mendelian ratios. We 
confirmed the absence of CHCHD10 expression by Western blot of 
homogenates from various tissues of CHCHD10 homozygote KO mice, 
including brain, skeletal muscle and heart (Figure 3-17 B). Heterozygote and 
homozygote males and females were viable and did not exhibit any gross 
phenotypic abnormalities from birth through early adulthood (up to 200 days of 
age).  
Figure 3-17. CHCHD10KO mice 
A. Four exons of CHCHD10 are indicated in grey. Black arrowhead 
indicates location of single nucleotide insertion in CHCHD10KO. B. 
Representative Western blot of brain, skeletal muscle (gastrocnemius) and 
heart homogenate from adult wild type (WT) and CHCHD10KO (KO) mice. 
100 μg protein was loaded per sample. Membrane was probed with 
antibodies against CHCHD10, CHCHD2 and Tim23 (mitochondrial loading 
control). 
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Since it was previously suggested that CHCHD10 plays a role in 
mitochondrial cristae maintenance using cultured cells from patients affected 
by CHCHD10 mutations (Genin et al., 2016), we wanted to investigate cristae 
morphology and overall mitochondrial ultrastructure by electron microscopy in 
vivo in the CHCHD10KO tissues. First, we performed immunohistochemistry 
with CHCHD10 antibodies in wild type and CHCHD10KO brain sections to 
Figure 3-18. CHCHD10 immunohistochemistry 
A. CHCHD10 immunoreactivity in brain section containing substantia nigra 
(SN) region from wild type (WT) mouse. B.  CHCHD10 immunoreactivity in 
brain section containing SN from CHCHD10KO mouse. Representative 
images in A and B captured at 2X magnification. Bar = 50 μm. PAG = 
periaqueductal gray, IPN = interpeduncular nucleus. C. CHCHD10 
immunoreactivity in SN from WT mice. D. CHCHD10 immunoreactivity in SN 
from CHCHD10KO mouse. Representative images in C and D captured at 
20X magnification. Bar =10 μm. 
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determine in which brain regions CHCHD10 is expressed. CHCHD10 staining 
was not homogeneous in the brain; rather, it was confined to particular brain 
regions, including the deep cerebellar nuclei, the ventricular lining, and most 
remarkably the substantia nigra (Figure 3-18 A, C). CHCHD10KO brain was 
used to confirm the specificity of the CHCHD10 antibody staining (Figure 3-18 
B, D). Because of the specific expression of CHCHD10 in this area, and 
because of the association of CHCHD10 and CHCHD2 with PD (Ogaki et al., 
2015; Shi et al., 2016; Rubino et al., 2017), we examined the substantia nigra 
of 100 days old wild type and CHCHD10KO mice by electron microscopy. 
Dopaminergic neuronal processes were identified by tyrosine hydroxylase 
(TH) immunoreactivity. We did not detect mitochondrial ultrastructural 
abnormalities in dopaminergic processes or in the other cell types in this brain 
region (Figure 3-19). In wild type and CHCHD10KO adult mouse skeletal 
muscle (soleus, Figure 3-20 A) and heart (Figure 3-20 B), where the protein is 
highly expressed (Figure 3-15), we did not observe abnormal cristae or other 
mitochondrial structural abnormalities. In heart, however, we noticed dark, 
electron dense round structures (Figure 3-20 B) localized in the region 
between sarcomeres, which contain heart mitochondria. These nature of these 
structures remains to be elucidated, but the morphology suggests that they 
could be lysosomes. Interestingly these structures were not connected with 
mitochondrial membranes, but were always in very close proximity to 
mitochondria. 
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We also studied mitochondrial bioenergetics in the brain, skeletal 
muscle, and heart of CHCHD10KO at 100 days of age. Mitochondria isolated 
from forebrain did not display differences in oxygen consumption (Figure 3-21 
A), COX activity (Figure 3-21 B), or ATP synthesis (Figure 3-21 C), in 
CHCHD10KO compared to wild type. Also, brain mitochondrial calcium 
Figure 3-19. CHCHD10KO brain electron microscopy 
Representative electron micrographs of WT (A, C) and CHCHD10KO (B, 
D) substantia nigra, showing TH-immunoreactive dendrites (TH-D). m = 
example mitochondria. Bar = 500 nm. 
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capacity of control and CHCHD10KO was similar (Figure 3-21 D). 
Mitochondria isolated from skeletal muscle (gastrocnemius) had decreased 
ADP-stimulated respiration (Figure 3-21 E), but not COX activity (Figure 3-21 
F) or ATP synthesis  (Figure 3-21 G) differences relative to wild type. There 
were no differences in respiration (Figure 3-21 H) or ATP synthesis (Figure 3-
21 I) between heart mitochondria from CHCHD10KO and wild type controls. 
Taken together, these data suggest that CHCHD10KO has tissue 
specific effects, resulting in a moderate decline in respiration in skeletal 
muscle, but not in other tissues examined. This decline in muscle, however, 
did not result in an ATP synthesis defect. Importantly, while there was an 
abnormal accumulation of electron-dense structures in CHCHD10KO heart, 
the lack of changes in mitochondrial ultrastructure in any tissue studied does 
not support the hypothesis that CHCHD10 is required for mitochondrial cristae 
maintenance.  
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Figure 3-20. CHCHD10KO skeletal muscle and heart electron microscopy 
A. Representative electron micrograph of WT and CHCHD10KO skeletal 
muscle (soleus). B. Representative electron micrograph of WT and 
CHCHD10KO heart right ventricle wall. Arrowheads indicate round 
structures present in CHCHD10KO. m = mitochondria. Bar = 500nm.  
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Figure 3-21. CHCHD10KO mouse bioenergetics 
A. Oxygen consumption rate of wild type (WT) and CHCHD10KO brain 
mitochondria before (State 2) and after (State 3) ADP stimulation. n = 3 
animals per group. B. COX activity of WT and CHCDH10KO brain 
mitochondria. n = 3. C. ATP synthesis rate of WT and CHCDH10KO brain 
mitochondria. n = 3. D. Representative Fura-FF calcium capacity traces of 
WT and CHCHD10 KO brain mitochondria with one 25μM calcium addition 
and sequential 10μM calcium additions followed by a final addition of 1mM 
EGTA. E. Oxygen consumption rate of WT and CHCHD10KO skeletal 
muscle mitochondria. * p < 0.05, n = 7. F. COX activity in WT and 
CHCHD10KO skeletal muscle mitochondria. n = 3. G. ATP synthesis rate of 
WT and CHCDH10KO skeletal muscle mitochondria. n = 7. H. Oxygen 
consumption rate of WT and CHCHD10KO heart mitochondria. n = 4. I. ATP 
synthesis rate of WT and CHCDH10KO heart mitochondria. n = 4.  
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3.5.  Discussion 
 This study identified a functional and physical relationship between the 
mitochondrial IMS twin CX9C proteins CHCHD10 and CHCHD2 and examined 
the consequences of modulating their expression in vitro and in vivo. We first 
confirmed the mitochondrial intermembrane space localization of CHCHD10, 
and found that similarly to other mitochondrial twin CX9C proteins it requires 
the cysteine(s) in the C terminus for its mitochondrial localization. Surprisingly, 
we demonstrated that, in addition to the being soluble in the IMS, as 
previously reported (Bannwarth et al., 2014), CHCHD10 also associates with 
mitochondrial membranes. Interestingly, the TMpred software (Hofmann and 
Stoffel, 1993) for prediction of membrane-spanning regions of proteins, 
predicates one transmembrane region of CHCHD10 in exon 2, which is part of 
a highly conserved region containing many disease-associated mutations. 
 The homology between CHCHD10 and CHCHD2 led us to investigate 
their relationship. We found that these proteins bind to each other, and to the 
mitochondrial protein P32. It is important to note, however, that P32 is 
abundantly expressed, and only a small portion is pulled down with either 
CHCHD10 or CHCHD2. Since CHCHD10 and CHCHD2 are found in the 
mitochondrial IMS and P32 localizes to the mitochondrial matrix (Muta et al., 
1997), it is possible that they may interact while P32 is en route to the matrix, 
or that they may interact through the IM since P32 can associate with 
membranes (Jiang et al., 1999). Although we did not find evidence that 
modulating the expression of CHCHD10 or CHCHD2 affects the levels of P32 
in cells, we cannot yet exclude that it may affect its localization and function. 
The former will be investigated in vitro and in vivo by fractionating cells and 
tissue to assess the distribution of P32. The latter is complicated by the 
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multiplicity of proposed functional roles of P32, which range from complement 
response in immunity to apoptosis. 
 We demonstrated that acute loss of CHCHD10 in immortalized cells, 
such as HEK293 and HeLa cells, causes apoptosis independently of 
mitochondrial bioenergetic failure. Conversely, silencing of CHCHD2 did not 
induce death, confirming previously reported findings in lung cancer cells (Liu 
et al., 2015). Furthermore, silencing of both CHCHD2 and CHCHD10 did not 
have additive effects on cell death. This suggests that the two proteins do not 
overlap functionally, despite their sequence similarity and interaction. 
Interestingly, however, apoptotic cell death following CHCHD10 siRNA could 
be partially rescued by overexpressing either CHCHD10 or CHCHD2. 
Therefore, while the two proteins have different functions, they appear to 
participate in a common pathway. 
Relative to other mitochondrial proteins, CHCHD10 and CHCHD2 are 
rapidly turned over, with a half-life of less than a few hours. This observation 
does not support a structural role for either protein. Instead, it suggests that 
they could serve as chaperones, either for protein import, similar to other 
CXnC Tim proteins (Curran et al., 2002; Mesecke et al., 2005) or for metal 
transport, such as the CXnC proteins involved in copper transport and RC 
assembly (Horn et al., 2008; Horn et al., 2010). In addition or alternatively, 
CHCHD10 and CHCHD2 could be involved in signaling processes, as 
suggested by the nuclear translocation of CHCHD2 under hypoxic conditions 
to regulate COX isoforms (Aras et al., 2015).   
 CHCHD10 silencing by siRNA induces apoptosis in both HEK293 and 
HeLa cells, yet stable knockdown HEK293 cell lines with about 20% remaining 
protein and CHCHD10KO mice are viable. These results clearly indicate that 
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both immortalized cells in culture and differentiated cells in vivo can activate 
compensatory mechanisms to adapt to the loss of CHCHD10. Future work will 
investigate the functional consequences of CHCHD10 knockdown in additional 
cell lines and tissues. Gaining further insight into adaptive mechanisms that 
compensate for CHCHD10 loss will allow for a better understanding of 
CHCHD10 functions.  
The expression of CHCHD10 in mouse tissues appears to be similar to 
what has been previously shown in human tissue, with high expression in 
heart and liver (Bannwarth et al., 2014). Because CHCHD10 and CHCHD2 
mutations are associated with neurodegeneration, we were interested in 
exploring CHCHD10 expression in brain. This is particularly important because 
of the heterogeneity of the cellular composition of the brain. We demonstrated 
for the first time that CHCHD10 in the brain is localized to particular regions, 
including the substantia nigra, which is a vulnerable region in PD.  
This study is the first to generate and describe a CHCHD10KO animal 
model. The CHCHD10KO mice do not display obvious motor symptoms 
reminiscent of PD or other human diseases, at least up to 200 days of age, the 
latest time at which we have observed their gross phenotype during breeding 
and handling for experiments. Longitudinal observations, pathology studies, 
and behavioral tests, such as for motor coordination, will be performed in 
collaboration with The Jackson Laboratories to determine whether these mice 
have more subtle behavioral phenotypes or develop age-related 
neurodegenerative phenotypes. Studies will also investigate CHCHD10KO 
responses to metabolic stress, such as high fat diet.  
In brain, muscle, and heart of the CHCHD10KO mouse we did not 
detect mitochondrial cristae abnormalities that were described in mutant 
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CHCHD10 patient fibroblasts (Genin et al., 2016). However, the mutations 
may not cause a loss of function, especially because most of the familial forms 
of ALS, FTD, and myopathy reported were autosomal dominant with variable 
penetrance and phenotypes. Therefore, it is likely that the mutants act by 
disrupting mitochondrial functions and structure in a manner independent from 
the normal function of CHCHD10. A similar scenario is illustrated by the well-
characterized forms of ALS caused by autosomal dominant SOD1 mutations, 
in which mitochondria become damaged by mutant protein aggregation 
(Igoudjil et al., 2011), irrespective of superoxide dismutase activity. We have 
generated cellular and mouse transgenic models of disease-associated 
mutant CHCHD10 in order to investigate this hypothesis. 
In summary, this study provides novel insight into the function of 
CHCHD10 and its interactions with mitochondrial proteins CHCHD2 and P32. 
It also generated and characterized novel genetic models of CHCHD10 
modulation in vitro and in vivo. Presently, these findings are being extended to 
the investigation of disease-associated CHCHD10 mutations, and to cellular 
mechanisms underlying ALS and other related diseases. 
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4.  CONCLUDING REMARKS 
 
Understanding and treating brain diseases has proven to be particularly 
challenging, which is not surprising giving the complexity and heterogeneity of 
the brain and the cell types within it. The evidence for mitochondrial 
dysfunction at the core of such diseases continues to accumulate, but 
targeting mitochondria for therapy is difficult. Targeting mitochondria is 
challenging because the mechanisms of mitochondrial involvement in disease 
are not fully understood. Furthermore, while much is known about the most 
studied proteins in mitochondria, many annotated mitochondrial proteins have 
yet unknown function (Pagliarini et al., 2008). At the start of this thesis work, it 
was estimated that up to 36% of mitochondrial proteins have no clearly 
established biochemical function and roughly 397 genes encoding 
mitochondrial proteins are associated with human diseases (Pagliarini and 
Rutter, 2013). In a more recent analysis (Floyd et al., 2016) using an updated 
inventory of mitochondrial proteins (Calvo et al., 2016), ~20% of the 
mammalian mitochondrial proteome was considered uncharacterized. The list 
of uncharacterized proteins includes CHCHD10, CHCHD2, and other twin 
CX9C proteins. The uncharacterized 20% mitochondrial proteins could even 
be an underestimation, as proteins that are not necessarily “mitochondrial” 
have dual localizations in mitochondria and other cellular compartments are 
constantly being uncovered.  Thus, a better characterization of the 
mitochondrial proteome can reveal aspects of both mitochondrial physiology 
and new diseases genes and pathways. 
In this dissertation, we investigated the function of two proteins with 
unexpected, yet important disease implications. ERβ is not considered a 
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mitochondrial protein per se because of its known transcriptional roles in the 
nucleus. However, it also has a mitochondrial localization that cannot be 
overlooked. This work is the first to identify a role for mitochondrial ERβ in 
brain MPT regulation. The molecular composition of the MPT pore is not well 
understood, but the discovery of a novel regulator could lead to a better 
understanding of MPT. We find a CypD-dependent sex difference in calcium 
induced MPT in brain. While the observed sex difference in isolated 
mitochondria was not dependent on ERβ, the possibility that modulation of this 
ERβ-CypD axis could affect brain injury outcomes warrants further 
investigation. In the future, for example, we would like to manipulate ERβ in an 
in vivo stroke model.  
We also examined the function of the mitochondrial protein CHCHD10 
using cellular and animal models. Recently mutations in CHCHD10 have 
emerged as genetic causes of neurodegenerative diseases, but very little is 
known about the protein itself. We identified a functional and physical 
relationship between CHCHD10 and its homolog CHCHD2, and characterized 
the phenotype of CHCHD10 silencing in cell culture and animal models. Our 
findings partly challenge current theories on the localization and function of 
CHCHD10. Experiments to achieve a deeper understanding of the function of 
CHCHD10 in mitochondria as well as the effects of the mutations are ongoing. 
Studies of genetic causes of neurodegeneration have often contributed to 
revealing novel pathogenic pathways that could extend to the most common 
sporadic forms of the diseases. Such discoveries will be crucial for identifying 
therapeutic targets.  
In addition to the main body of work that is described in this thesis, the 
appendix includes a recently published manuscript, of which I am a co-first 
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author, which describes a sex difference in the mitochondrial IMS unfolded 
protein response in a mouse model of ALS. In both this paper and the studies 
of brain MPT described above, we focused on sex differences in mitochondrial 
phenomena in stroke and neurodegenerative diseases. There has been a 
recent emphasis on the importance of including the effects of sex and gender 
in biological research, and the NIH has recently mandated the inclusion of 
females in experimental studies and the analysis of data by sex (Clayton and 
Collins, 2014). This is particularly important, as there are many human 
diseases, which have incidences and outcomes that differ between males and 
females. Sex differences in mitochondrial dysfunction and other mechanisms 
involved in disease pathogenesis need to be understood so that safe and 
effective therapies can be developed. 
Overall, this work investigates novel functions of mitochondrial proteins 
and paves the way for future studies of these proteins in neurological 
diseases.  
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APPENDIX 
 
SEX SPECIFIC ACTIVATION OF THE ERα AXIS OF THE MITOCHONDRIAL 
UPR (UPRMT) IN THE G93A-SOD1 MOUSE MODEL OF FAMILIAL ALS * 
 
Abstract  
The mitochondrial unfolded protein response (UPRmt) is a 
transcriptional program aimed at restoring proteostasis in mitochondria. 
Upregulation of mitochondrial matrix proteases and heat shock proteins was 
initially described. Soon thereafter, a distinct UPRmt induced by misfolded 
proteins in the mitochondrial intermembrane space (IMS) and mediated by the 
estrogen receptor alpha (ERα), was found to upregulate the proteasome and 
the IMS protease OMI. However, the IMS-UPRmt was never studied in a 
neurodegenerative disease in vivo. Thus, we investigated the IMS-UPRmt in 
the G93A-SOD1 mouse model of familial ALS, since mutant SOD1 is known to 
accumulate in the IMS of neural tissue and cause mitochondrial dysfunction. 
As the ERα is most active in females, we postulated that a differential 
involvement of the IMS-UPRmt could be linked to the longer lifespan of females 
in the G93A-SOD1 mouse. We found a significant sex difference in the IMS-
UPRmt, because the spinal cords of female, but not male, G93A-SOD1 mice 
showed elevation of OMI and proteasome activity. Then, using a mouse in 
which G93A-SOD1 was selectively targeted to the IMS, we demonstrated that 
the IMS-UPRmt could be specifically initiated by mutant SOD1 localized in the 
IMS. Furthermore, we showed that, in the absence of ERα, G93A-SOD1 failed 
to activate OMI and the proteasome, confirming the ERα dependence of the 
response. Taken together, these results demonstrate the IMS-UPRmt 
activation in SOD1 familial ALS, and suggest that sex differences in the 
disease phenotype could be linked to differential activation of the ERα axis of 
the IMS-UPRmt. 
* Sex specific activation of the ERα axis of the mitochondrial UPR (UPRmt) in 
the G93A-SOD1 mouse model of familial ALS. Hum Mol Genet 2017; 26 
(7):1318-1327. doi: 10.1093/hmg/ddx049 
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Introduction 
Mutations in the Cu,Zn,superoxide dismutase (SOD1) are responsible 
for approximately 20% of fALS (Rosen, 1993).The pathophysiology of SOD1-
ALS is not completely understood, and different mechanisms may participate 
in pathogenesis (Ilieva et al., 2009), including mitochondrial dysfunction 
(Hervias et al., 2006; Shi et al., 2010). The G93A amino acid substitution in 
SOD1 is one of the most extensively studied mutations, both in cultured cells 
and in mouse models of the disease. Transgenic mice express high levels of 
G93A-SOD1 ubiquitously, under the control of the SOD1 endogenous 
promoter. They develop rapid motor neuron degeneration, resulting in 
paralysis and death by 4 or 5 months of age, depending on the genetic 
background (Gurney et al., 1994).The prevalent theory for the pathogenesis of 
mutant SOD1 involves a gain of toxic function of G93A-SOD1. One critical 
observation is that misfolded SOD1 localizes to multiple cell compartments, 
including mitochondria. Mutant SOD1 accumulates on the mitochondrial outer 
membrane (Vande Velde et al., 2008) where it interacts with some crucial 
proteins, such as Bcl2 (Pedrini et al., 2010) and VDAC (Israelson et al., 2010). 
However, mutant SOD1 also localizes inside the mitochondrial IMS, where it 
accumulates and misfolds, potentially interfering with the assembly and 
maturation of mitochondrial proteins (Vijayvergiya et al., 2005; Ferri et al., 
2006; Kawamata and Manfredi, 2008). The pathogenic role of the IMS pool of 
mutant SOD1 is also supported by evidence from cultured motor neurons, 
where it causes mitochondrial functional, morphological, and axonal transport 
abnormalities (Cozzolino et al., 2009; Magrane et al., 2009). Furthermore, we 
recently developed transgenic mice containing G93A-SOD1 in the IMS but not 
the cytoplasm (G93A IMS-SOD1), and showed that these mice develop some 
of the symptoms of ALS, including motor defects and mitochondrial 
abnormalities (Igoudjil et al., 2011). However, one important difference 
between this mouse and the G93A-SOD1 mouse (where G93A-SOD1 is 
present in both the cytosol and the IMS) is that the IMS-only mice develop 
disease symptoms almost one year later. Taken together, these findings 
indicate that eventually the accumulation of misfolded G93A-SOD1 in the IMS 
is toxic for mitochondria and neurons, but they also suggest that IMS 
proteotoxic stress may initially activate cytoprotective responses.  
A mitochondrial unfolded protein response (UPRmt) was first described 
as a consequence of the accumulation of misfolded proteins in the matrix 
(Martinus et al., 1996; Zhao et al., 2002). These studies revealed that CHOP 
promotes the expression of matrix protein quality control systems, such as 
proteases and chaperones, namely hsp10 and hsp60 (Martinus et al., 1996; 
Zhao et al., 2002). Unlike in the matrix, there are no chaperones in the IMS, 
and while AAA proteases face the IMS, none of their substrates are IMS 
proteins (Augustin et al., 2005; Koppen and Langer, 2007). 
We previously reported that the proteasome plays an active role in 
limiting the accumulation of misfolded proteins in the IMS (Radke et al., 2008), 
and that the IMS protease OMI plays a role in IMS protein quality control 
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(Radke et al., 2008). Then, we reported that accumulation of misfolded 
proteins in the IMS did not activate the CHOP-hsp60 axis of the UPRmt, but 
rather a distinct response driven by the estrogen receptor alpha (ERα) (Papa 
and Germain, 2011). The ERα axis of the UPRmt implicates a cross talk 
between phosphorylated Akt and the ERα, expression of the mitochondrial 
transcription factor NRF-1, and most importantly for the current study, the up-
regulation of the proteasome and OMI (Papa and Germain, 2011). 
The ERα dependency of the IMS-UPRmt raises intriguing questions. 
First, since not all cell types express ERα, how do ERα negative cells cope 
with accumulation of misfolded proteins in the IMS? Our studies in breast 
cancer cells suggested that in absence of the ERα, the CHOP-hsp60 could 
partially compensate (Papa and Germain, 2014). Second, since the ERα is 
most active in females, do the mechanisms to cope with proteotoxic stress in 
the IMS caused by misfolding of disease related mutant proteins, such as 
SOD1, differ between sexes, and if so, do they correlate with sex differences 
in the disease phenotype? To address this question we studied a G93A-SOD1 
mouse model of familial ALS, in which females have a longer lifespan than 
males (Heiman-Patterson et al., 2005), in order to evaluate whether 
differences in the activation of the IMS-UPRmt could be detected in vivo and 
correlated with the sexual dimorphism. These questions could be directly 
relevant to human ALS, since the frequency of the disease is significantly 
higher in males than in females (McCombe and Henderson, 2010), suggesting 
that sex hormones and receptors may be involved in sexual dimorphism in 
ALS.  
 
Materials and Methods 
Animals 
We used the B6SJL-Tg(SOD1*G93A)1Gur/J, the Tg(SOD1)2Gur, the 
B6SJL-Tg(Prnp-Immt/SOD1*G93A)7Gmnf/J, and the B6SJL-Tg(Prnp-
Immt/SOD1)1Gmnf/J from The Jackson Laboratory. Estrogen Receptor α 
knockout animals with the G93A-SOD1 mutation (ERαKO-G93A) in the 
C57BL/6J congenic background were generated by crossing the G93A-SOD1 
line (B6.Cg-Tg (SOD1-G93A)1Gur/J) with ERαKO heterozygote mice 
(B6.129P2-Esr1tm1Ksk/J), both available from The Jackson Laboratory. 
Females heterozygous for ERαKO were bred with males heterozygous for 
ERαKO, which also had the G93A-SOD1 mutation. At the indicated ages, 
animals were sacrificed and tissues harvested in storage solution (10mM Tris 
pH 7.4, 320 mM sucrose, 20% DMSO), and immediately frozen in liquid 
nitrogen.  
All experiments were approved by the Weill Cornell Medical College 
Institutional Animal Care and Use Committee. Principles of laboratory animal 
care" (NIH publication No. 86-23, revised 1985) were followed, as well as 
specific national laws (e.g. the current version of the German Law on the 
Protection of Animals), where applicable. 
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Western blotting  
Spinal cords were lysed in NP-40 lysis buffer, sonicated for 1 sec at an 
amplitude of 20% and centrifuged at 14,000 rpm at 4°C for 20 min. Proteins 
were separated on 10% or 4-20% Mini-PROTEAN TGX gels (Bio-Rad,CA) and 
transferred to nitrocellulose blotting membrane (GE Healthcare Life Sciences). 
Membranes were probed with primary antibodies against phosphorylated-Akt 
(Cell Signaling), Akt (Cell Signaling), Omi/HtrA2 (Biovison), NRF-1 (Abcam), 
hsp60 (BD Bioscience), CHOP (Cell Signaling), BiP (BD Bioscience), Ub-48 
(EMD Millipore) and Actin (EMD Millipore) overnight at 4°C. Blots were then 
probed with horseradish peroxidase-conjugated anti-mouse (Jackson 
ImmunoResearch) or anti-rabbit (Thermo Scientific) secondary antibodies and 
detected using enhanced chemiluminescence (GE Healthcare or Millipore). 
Proteasome assay 
Spinal cord lysates (10 μg) were incubated in proteasome activity assay 
buffer (50mM Tris-HCl, pH 7.5) with 10 μM trypsin fluorogenic substrate Ac-
Ala-Leu-Ala-AMC (Ac-ALA-AMC) or chymotrypsin fluorogenic substrate 
succinly-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin (Suc-LLVY-AMC), or 
caspase fluorogenic substrates N-acetyl-Gly-Pro-Leu-Ala-AMC (Ac-GPLA-
AMC) for 3 hours at 37° C. Release of free hydrolysed 7-amino-4-
methylcoumarin (AMC) groups was measured at 380 nm excitation and 
460nm emission using SpectraMax M5e microplate reader (Molecular 
Devices). 
Statistical analysis 
Data is presented as mean ± SEM. Two-tailed Students’s t-test was 
used to determine the significance between two datasets. *p<0.05 was 
considered as statistically significant. All statistical analysis was performed 
using GraphPad Instat software. 
 
Results 
The CHOP/hsp60 axis of the UPRmt is transiently activated in females during 
the symptomatic phase of the G93A-SOD1 model of fALS. 
The first described axis of the UPRmt is regulated by the transcription 
factor CHOP, which promotes the expression of proteases as well as the 
chaperone hsp60 (Martinus et al., 1996; Zhao et al., 2002). As a 
consequence, the promoter of hsp60 has been widely used in subsequent 
studies of the UPRmt, notably in C. elegans (Benedetti et al., 2006) (Haynes 
et al., 2007; Fiorese et al., 2016; Lin et al., 2016) (Durieux et al., 2011; 
Nargund et al., 2012; Mohrin et al., 2015; Nargund et al., 2015) (Tian et al., 
2016). 
We therefore initiated our analysis of the UPRmt in the spinal cord of 
G93A-SOD1 mouse model of familial ALS by monitoring the levels of CHOP 
and hsp60. G93A-SOD1 transgenic mice develop an aggressive form of motor 
neuron disease, with paralysis onset at 90 days of age and death at 130 days 
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of age (Gurney et al., 1994). Therefore, studies were performed in male and 
female G93A-SOD1 mice and non-transgenic control littermates at different  
  
Appendix Figure 1. The CHOP/hsp60 axis is activated during the 
symptomatic phase in the G93A-SOD1 model of fALS. (A) Representative 
western blot of hsp60 and CHOP in 2 non-transgenic males and 2 G93A-
SOD1 males at day 30, 60, 90 and 120. β-actin was used as a loading 
control. (B) Quantification of the level of CHOP at each time point in 
males. n = 4. The level of CHOP relative to β-actin was determined for 4 
non-transgenic males and the average of the 4 values set to 100 percent 
for each time point. The average level of CHOP relative to β-actin was 
also determined in 4 G93A-SOD1 transgenic males at each time point and 
expressed as a percentage change relative to the non-transgenic males 
(dotted line). (C) Quantification of the level of hsp60 in males, as in B. 
n = 4. (D) Representative western blot of hsp60 and CHOP in 2 non-
transgenic females and 2 G93A-SOD1 females at day 30, 60, 90 and 120. 
β-actin was used as a loading control. (E) Quantification of the level of 
CHOP in females, as in B. n = 4. (F) Quantification of the level of hsp60 in 
females, as in B. n = 4. (G) Representative western blot of BiP in 2 non-
transgenic males and 2 G93A-SOD1 males at day 30, 60, 90 and 120. β-
actin was used as a loading control. (H) Quantification of the level of BiP in 
males, as in B. n = 4. (I) Representative western blot of BiP in 2 non-
transgenic females and 2 G93A-SOD1 females at day 30, 60, 90 and 120. 
β-actin was used as a loading control. (J) Quantification of the level of BiP 
in females, as in B. n = 4. *P < 0.05 when compared to the respective non-
transgenic. 
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ages, starting at 30 and 60 days, representing pre-symptomatic disease 
stages, and at 90 and 120 days, representing early and late symptomatic 
stages, respectively.  
To study the effect of the mutant transgene on UPRmt markers in spinal 
cord, protein levels were normalized to non-transgenic control values at each 
age. We found that in males, CHOP levels were significantly lower as 
compared to age-matched transgenic males at 30 days (Fig. 1A,B). However, 
at day 60 and thereafter CHOP levels in mutant mice were no longer lower. In 
females, there was no CHOP decrease at 30 days, and remarkably a 
robust CHOP increase was observed during the symptomatic phase, at 90 and 
120 days (Fig. 1D,E). In female G93A-SOD1 mice, but not in males (Fig. 
1A,C), hsp60 was significantly higher at 90 days of age, but it reverted to 
control levels at 120 days (Fig. 1D,F).  
Since CHOP also regulates the expression of the chaperone BiP during 
the UPRER independently of its role in the UPRmt, we tested whether BiP is 
elevated in transgenic females. We found that the levels of BiP closely 
matched CHOP levels at every time point tested (Fig. 1G,H). This finding is in 
agreement with the extensively characterized ER-stress activation in ALS mice 
(Matus et al., 2013). To test whether this response was specific to regions of 
the CNS affected by the disease, such as the spinal cord. CHOP and hsp60 
were measured in the cerebellum, which is unaffected in G93A-SOD1 mice, of 
females at 60 and 120 days of age, when a significant increase was observed 
in the spinal cord. We found no significant differences in CHOP or hsp60 in the 
cerebellum of G93A-SOD1 transgenic mice compared to non-transgenic mice 
(Suppl. Fig 1, A, B, C), suggesting that the response did not take place in 
unaffected regions of the CNS.  
Taken together these results indicate that in ALS spinal cord there is 
activation of CHOP-mediated stress responses. However, there was a clear 
sex difference in CHOP axis activation, since increases of all markers at 
symptomatic stages were only observed in G93A-SOD1 females, whereas in 
males the responses were absent, and even below control levels at early 
stages.  
Sex-specific activation of the ERα axis of the UPRmt in G93A-SOD1 mice. 
We had previously reported that accumulation of misfolded proteins in 
the mitochondrial IMS in breast cancer cells activates a UPRmt response 
pathway initiated by the phosphorylation of Akt and leading to activation of 
ERα, expression of the transcription factor NRF-1, increase of the IMS 
protease OMI, and upregulation of proteasome activity (Papa and Germain, 
2011). The upregulation of OMI and proteasome activities was instrumental in 
promoting the degradation of misfolded IMS proteins (Papa and Germain, 
2011) (Radke et al., 2008). Since misfolded SOD1 is known to accumulate 
and aggregate in the IMS (Ferri et al., 2006; Kawamata and Manfredi, 2010) 
we investigated whether the ERα axis of the UPRmt was activated in the 
G93A-SOD1 mouse spinal cord. 
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In males, we found an early elevation in Akt phosphorylation, NRF-1 
and OMI at day 30 relative to non-transgenic mice (Fig. 2A, B, C, D). However 
the levels of phospho-Akt, NRF-1, and OMI decreased in G93A-SOD1 mice at 
later time points, suggesting that in these mice the IMS-UPRmt started to 
decline as early as 60 days of age. In females, neither phospho-Akt nor NRF-1 
were elevated relative to non-transgenic mice at any of the time points tested 
(Fig. 2E, F, G). However, OMI was markedly elevated in female G93A-SOD1 
mice at the symptomatic stage (Fig. 2H). We then tested whether the  
Appendix Supplementary Figure 1. The CHOP/hsp60 and the ER axes 
of the UPRmt are not activated in the cerebellum during the symptomatic 
phase in the G93A-SOD1 model of fALS. A) Representative western blot 
of CHOP, hsp60 and OMI in 4 non-transgenic females and 4 G93A-
SOD1 females at day 90 and 120. β-actin was used as a loading control. 
B) Quantification of the level of CHOP at each time point in females. n=4. 
The level of CHOP relative to β-actin was determined for 4 non-
transgenic females and the average of the 4 values set to 100 percent for 
each time point. The average level of CHOP relative to β-actin was also 
determined in 4 G93A-SOD1 transgenic females at each time point and 
expressed as a percentage change relative to the non-transgenic females 
value (dotted line). C) Quantification of the level of hsp60 in females, as 
in B. n=4. D) Quantification of the level of OMI in females, as in B. E) The 
trypsin-like activity of the 26S proteasome in 4 non-transgenic females 
(black bar) and 4 G93A-SOD1 transgenic females (gray bar) at day 90 
and 120. n=4. 
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Appendix Figure 2. The UPRmt is activated during the symptomatic 
phase the G93A-SOD1 model of fALS. (A) Representative western blot 
of phospho-Akt, Akt, NRF-1 and OMI in 2 non-transgenic males and 2 
G93A-SOD1 males at day 30, 60, 90 and 120. β-actin was used as a 
loading control. (B) Quantification of the ratio of phospho-Akt to total Akt 
at each time point in males. n = 4. The ratio of phospho-Akt to total Akt 
was determined for 4 non-transgenic males and the average of the 4 
values set to 100 percent for each time point. The ratio of phospho-Akt to 
total Akt was also determined in 4 G93A-SOD1 transgenic males at each 
time point and expressed as a percentage change relative to the non-
transgenic males value (dotted line). (C) Quantification of the level of 
NRF-1 in males, as in in B. n = 4. (D) Quantification of the level of OMI in 
males, as in B. n = 4. (E) Representative western blot of phospho-Akt, 
Akt, NRF-1 and OMI in 2 non-transgenic females and 2 G93A-SOD1 
females at day 30, 60, 90 and 120. β-actin was used as a loading 
control. (F) Quantification of the ratio of phospho-Akt to total Akt in 
females, as in B. n = 4. (G) Quantification of the level of NRF-1 in 
females, as in B. n = 4. (H) Quantification of the level of OMI in females, 
as in B. n = 4. *P < 0.05 when compared to the respective non-
transgenic. 
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activation of OMI is specific to the spinal cord. We found no significant 
difference in OMI in the cerebellum of G93A-SOD1 transgenic mice compared 
to non-transgenic mice (Suppl. Fig 1D), indicating that the effect was tissue 
specific. We then monitored the activity of the proteasome in spinal cord 
homogenates of males and females over the course of disease progression. 
First, proteasome activity was measured fluorimetrically, using small peptide 
substrates of the trypsin-like, chymotrypsin-like, and caspase-like activities. As 
previously reported (Papa and Germain, 2011), we found that the trypsin-like 
activity of the proteasome was decreased in male G93A-SOD1 mice 
Appendix Figure 3. Proteasome activity is decreased in G93A-SOD1 
males. (A) The trypsin-like activity of the 26S proteasome in 4 non-
transgenic males (black bar) and 4 G93A-SOD1 males (gray bar). n = 4. 
(B) The chymotrypsin-like activity of the 26S proteasome in 4 non-
transgenic males (black bar) and 4 G93A-SOD1 transgenic males (gray 
bar). n = 4. (C) The caspase-like activity of the 26S proteasome in 4 
non-transgenic males (black bar) and 4 G93A-SOD1 transgenic males 
(gray bar). n = 4. (D) Representative Western blot of total lysine 48 
ubiquitin chains in 2 non-transgenic and 2 G93A-SOD1 transgenic 
males. β-actin was used as a loading control. (E) The trypsin-like 
activity of the 26S proteasome in 4 non-transgenic females (black bar) 
and 4 G93A-SOD1 transgenic females (gray bar). n = 4. (F) The 
chymotrypsin-like activity of the 26S proteasome in 4 non-transgenic 
females (black bar) and 4 G93A-SOD1 transgenic females (gray bar). 
n = 4. (G) The caspase-like activity of the 26S proteasome in 4 non-
transgenic females (black bar) and 4 G93A-SOD1 transgenic females 
(gray bar). n = 4. (H) Representative Western blot of total lysine-48 
ubiquitin chains in 2 non-transgenic and 2 G93A-SOD1 transgenic 
females. β−actin was used as a loading control. *P < 0.05 when 
compared to the respective non-transgenic. 
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compared to age matched controls (Fig. 3A). In females, there was no decline 
of the activity at any time point; meanwhile, the trypsin-like and chymotrypsin-
like activities were significantly increased at 120 days of age (Fig. 3E,F).  
Again, we found no significant difference in the activity of the proteasome in 
the cerebellum of G93A-SOD1 transgenic females at these time points (Suppl. 
Fig 1E). Since the proteasome degrades ubiquitinated proteins, we studied 
levels of ubiquitinated proteins by western blot, using an antibody against 
lysine-48 ubiquitin chains, which target proteins to the proteasome. We found 
Appendix Supplementary Figure 2. The ERα axis of the UPRmt is not 
activated in mice expressing wild-type SOD1. A) Representative 
western blot of OMI in 4 wild type (WT) SOD1 transgenic females 
and 4 G93A-SOD1 females at day 30, 60, 90 and 120. β-actin was 
used as a loading control. B) Quantification of the level of OMI at 
each time point in females in A. n=4. C) Western blot of total 
ubiquitin in WT-SOD1 and G93A-SOD1 transgenic males at day 30, 
60, 90 and 120. β-actin was used as a loading control. D) Western 
blot of total ubiquitin in WT-SOD1 and G93A-SOD1 transgenic 
females at day 30, 60, 90 and 120. β-actin was used as a loading 
control. E) Western blot of NRF-1 at day 60 in two WT IMS-SOD1 
transgenic females and two G93A IMS-SOD1 transgenic females. 
Quantification is shown on the right. F) Western blot of OMI at day 
120 in two WT IMS-SOD1 transgenic females and two G93A IMS-
SOD1 transgenic females. Quantification is shown on the right. 
each time point in females in A. n=4.  
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a general increase in the levels of proteins reactive to Ub48 antibodies in 
G93A-SOD1 males, which was most evident at 30 and 120 days (Fig. 3D). 
This finding was consistent with a decrease in the activity of the proteasome in 
males. In female G93A-SOD1 mice, there was no increase in the levels of 
proteins reactive to Ub48 antibodies (Fig. 3H), in agreement with the 
preserved proteasome activity.  
Since the G93A-SOD1 mouse overexpresses the protein, to exclude 
that observed effects were due to overexpression of SOD1, we examined the 
levels of OMI and ubiquitin in the spinal cord of mice overexpressing wild type 
SOD1. We found that G93A-SOD1 females showed increased OMI relative to 
wild type SOD1 females (Suppl. Fig 2A, B). The level of spinal cord protein 
ubiquitination was also increased in G93A-SOD1 males compared to wild type 
SOD1 males (Suppl. Fig. 2C), but was decreased in G93A-SOD1 females 
compared to wild type SOD1 females (Suppl. Fig. 2D). These results indicated 
that the effects on OMI and the proteasome are caused by mutant, and not by 
wild type, SOD1 expression.  
Overall, these findings suggest significant sex differences in the 
activation of the IMS-UPRmt pathway in the G93A-SOD1 mouse spinal cord. In 
females, we observed an increase in OMI levels and proteasome activity in 
symptomatic disease stages, whereas the absence of this response in males 
was associated with increased levels of ubiquitinated proteins.  
Activation of the UPRmt is observed in G93A IMS-SOD1 mice. 
SOD1 is localized both in the cytosolic and mitochondrial IMS cellular 
compartment (Okado-Matsumoto and Fridovich, 2001). Therefore, to 
determine whether SOD1 localized in the IMS was specifically involved in 
activating the UPRmt we took advantage of a transgenic mouse in which 
G93A-SOD1 is targeted selectively to the IMS by the addition of an N-terminus 
targeting sequence (G93A IMS-SOD1). As a result, G93A-SOD1 is absent 
from the cytosol and only concentrated in the IMS (Igoudjil et al., 2011). Since 
the pre-symptomatic phase is much longer in G93A IMS-SOD1mice than in 
the untargeted model (Igoudjil et al., 2011), we only analyzed the UPRmt 
markers and proteasome activity at 60, 90 and 120 days. 
In G93A IMS-SOD1 males, NRF-1 was significantly increased relative 
to the non-transgenic controls only at day 60, while no other markers of the 
IMS-UPRmt were significantly different  (Fig. 4A, B, C, D). In females, while 
phospho-Akt did not differ from controls, NRF-1 was significantly increased 
G93A IMS-SOD1 at 60 days (Fig. 4E, F, G). This observation indicates that, 
unlike in the untargeted model, mutant SOD1 targeted to the IMS leads to an 
early activation of NRF-1 in both males and females. Importantly, in female 
G93A IMS-SOD1 mice, OMI was significantly elevated compared to controls at 
120 days of age, similarly to the untargeted females (Fig. 4H). This suggested 
that localization of mutant SOD1 in the IMS was sufficient to cause OMI 
elevation in female mice. 
The activity of the proteasome in G93A IMS-SOD1 males was 
unaffected until 120 days of age, when a decrease in trypsin-like activity was 
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observed (Fig. 5A), while the other activities were unchanged at all time points 
(Fig. 5B, C). This suggested that IMS-restricted protein was less effective in 
causing proteasomal dysfunction than untargeted, mostly cytosolic, G93A-
SOD1. The accumulation of lysine-48 ubiquitin was less in G93A IMS-SOD1  
  
Appendix Figure 4. The UPR
mt
 is activated in G93A IMS-SOD1 mice. 
(A) Representative western blot of phospho-Akt, Akt, NRF-1 and OMI in 
2 non-transgenic males and 2 G93A IMS-SOD1 males at day 60, 90 
and 120. β-actin was used as a loading control. (B) Quantification of the 
ratio of phospho-Akt to total Akt at each time point in males. n = 4. The 
ratio of phospho-Akt to total Akt was determined for 4 non-transgenic 
males and the average of the 4 values set to 100 percent for each time 
point. The ratio of phospho-Akt to total Akt was also determined in 4 
G93A IMS-SOD1 transgenic males and the average of these 4 values 
was expressed as a percentage change relative to the non-transgenic 
males (dotted line). (C) Quantification of the level of NRF-1 in males, as 
in B. n = 4. (D) Quantification of the level of OMI in males, as in B. n = 4. 
(E) Representative western blot of phospho-Akt, Akt, NRF-1 and OMI in 
2 non-transgenic females and 2 G93A IMS-SOD1 females at day 60, 90 
and 120. β-actin was used as a loading control. (F) Quantification of the 
ratio of phospho-Akt to total Akt in females, as in B. n = 4. (G) 
Quantification of the level of NRF-1 in females, as in B. n = 4. (H) 
Quantification of the level of OMI in females, as in B. n = 4. *P < 0.05 
when compared to the respective non-transgenic. 
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Appendix Figure 5. Monitoring the proteasome activity in the G93A 
IMS-SOD1 mouse model over disease progression. (A) The trypsin-like 
activity of the 26S proteasome in 4 non-transgenic males (black bar) 
and 4 G93A IMS-SOD1 transgenic males (gray bar). n = 4. (B) The 
chymotrypsin-like activity of the 26S proteasome in 4 non-transgenic 
males (black bar) and 4 G93A IMS-SOD1 transgenic males (gray bar). 
n = 4. (C) The caspase-like activity of the 26S proteasome in 4 non-
transgenic males (black bar) and 4 G93A IMS-SOD1 transgenic males 
(gray bar). n = 4. (D) Representative Western blot of total lysine 48 
ubiquitin chains in 2 non-transgenic and 2 G93A IMS-SOD1 transgenic 
males. β-actin was used as a loading control. (E) The trypsin-like 
activity of the 26S proteasome in 4 non-transgenic females (black bar) 
and 4 G93A IMS-SOD1 transgenic females (gray bar). n = 4. (F) The 
chymotrypsin-like activity of the 26S proteasome in 4 non-transgenic 
females (black bar) and 4 G93A IMS-SOD1 transgenic females (gray 
bar). n = 4. (G) The caspase-like activity of the 26S proteasome in 4 
non-transgenic females (black bar) and 4 G93A IMS-SOD1 transgenic 
females (gray bar). n = 4. (H) Representative Western blot of total 
lysine-48 ubiquitin chains in 2 non-transgenic and 2 IMS-only G93A-
SOD1 transgenic females. β-actin was used as a loading control. 
*P < 0.05 when compared to respective non-transgenic. 
SOD1 transgenic females. β-actin was used as a loading control. 
*P < 0.05 when compared to respective non-transgenic. 
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males than age matched controls (Fig. 5D), further suggesting that the 
cytosolic, and not the IMS, G93A-SOD1 was responsible for proteasome 
impairment.  
In female G93A IMS-SOD1 mice, the proteasome activity was not 
decreased at any time point, and, similar to the untargeted G93A-SOD1 
females, the chymotrypsin activity was increased at 120 days of age (Fig. 5E, 
F, G). Like males, female G93A IMS-SOD1 mice did not exhibit an increase of 
lysine-48 ubiquitin (Fig. 5H). 
Having established that NRF-1 is increased at day 60 in male G93A IMS-
SOD1 mice and that OMI is elevated at day 120 in female G93A IMS-SOD1 
mice, we examined NRF-1 and OMI wild type IMS-SOD1 mice at 60 and 120 
days, respectively. We found that in both cases, the effect was specific to 
G93A IMS-SOD1 mice (Suppl. Fig. 2E, F). These results indicated that the 
effects on NRF-1 and OMI are caused by mutant, and not by wild type, SOD1 
in the mitochondrial IMS.  
Collectively, these results suggest that the IMS localization of G93A-
SOD1 is responsible for the activation of the IMS-UPRmt as demonstrated by 
the elevation of NRF-1 and OMI. They also suggest that the cytosolic 
localization of G93A-SOD1 is necessary to cause proteasomal dysfunction, 
which was absent in the G93A IMS-SOD1 mice.  
Genetic ablation of ERα in G93A-SOD1 mice abolishes the activation of OMI 
but stimulates the CHOP/hsp60 axis of the UPRmt. 
In cancer cells, we reported that inhibition of the ERα by shRNA 
prevented the activation of OMI in response to accumulation of misfolded 
proteins in the IMS (Papa and Germain, 2011). Since OMI was the most 
affected marker of the activation of the UPRmt in female G93A-SOD1 mice, we 
tested whether genetic ablation of the ERα in this model would affect the 
expression of OMI. We therefore crossed the G93A-SOD1 mouse with an ERα 
knockout mouse. We obtained wild type non transgenic mice, ERα knockout 
mice (ERαKO), and ERαKO-G93A-SOD1 mice. We tested the UPRmt markers 
-G93A-
SOD1 mice OMI was not upregulated relative to both ERα knockout and wild 
type non-transgenic controls (Fig. 6A, B).   
We then analyzed levels of CHOP and hsp60 in these mice. We found 
that in both male and female ERαKO-G93A-SOD1 mice there was an 
elevation in CHOP, which was more pronounced in females than in males 
(Fig. 6 C, D) and was not observed in G93A-SOD1 mice (Fig. 1). This result 
suggested that in the absence of the ERα-dependent axis of the UPRmt, an 
ERα-independent axis, involving CHOP, but not OMI, could be activated as a 
compensatory mechanism. This result is in agreement with our finding in 
breast cancer cell lines, where in the absence of ERα the accumulation of 
misfolded proteins in the IMS activates CHOP (Papa and Germain, 2014). 
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Appendix Figure 6. Genetic ablation of the ERα abolishes the activation of OMI 
but stimulates the CHOP/hsp60 axis of the UPR
mt
. (A) Western blot of non-
transgenic, ERαKO or ERαKO-G93A males (left) and females (right) of OMI, 
hsp60 and CHOP. β-actin is used as a loading control. All mice were harvested 
at day 60. (B) Quantification of the ratio of OMI to β−actin. For this experiment 
the number of mice per group varied: non-transgenic males, n = 6, ERαKO 
males, n= 4, ERαKO-G93A knockout males, n = 2, non-transgenic females, 
n = 4, ERαKO females, n = 3, ERαKO-G93A females, n = 8. Because n = 2 in 
some groups, the males and the females were combined to perform statistical 
analyses. (C) Quantification of the level of hsp60 in non-transgenic, ERαKO or 
ERαKO-G93A males and females. The quantification was performed as 
described in B. (D) Quantification of the level of CHOP in non-transgenic, 
ERαKO or ERαKO-G93A males and females. The quantification was 
performed as described in B. *P < 0.05 when compared to respective non-
transgenic. 
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Discussion 
The ERα axis of the UPRmt was first identified in breast cancer cells 
using accumulation of misfolded protein specifically in the IMS as a tool to 
dissect the relative contribution of the matrix and IMS in the activation of the 
UPRmt (Papa and Germain, 2011). However, in vivo validation of this pathway 
in a disease relevant mouse model of neurodegeneration was lacking. Since 
G93A-SOD1 misfolds and accumulates in the IMS, this mouse model was 
ideal to investigate the IMS-UPRmt in vivo in a mammalian model of familial 
ALS.  
The findings from this study confirmed previous observations and 
revealed a novel role of the IMS-specific axis of UPRmt. Our results concur 
with previous observations that the CHOP-hsp60 axis is activated (Mohrin et 
al., 2015) and the proteasome inhibited during disease progression (Kabashi 
and Durham, 2006). While these results validate the hypothesis that the 
UPRmt is active in G93A-SOD1 mice, they also bring additional information 
regarding these effects according to sex. Notably, while the proteasome was 
inhibited in males, it was activated in females. Differential proteasomal 
responses could have a disease-modifying function, but also directly 
participate in accumulation of misfolded SOD1 in mitochondria, since it was 
shown that degradation of IMS misfolded proteins involves the proteasome 
(Bragoszewski et al., 2013). 
In addition to proteasome activation, our data revealed that the IMS 
protease OMI is upregulated in females. Therefore, both components of IMS 
protein quality control are upregulated in females. This result is consistent with 
the more potent role of the ERα in females. 
The G93A IMS-SOD1 mouse model made it possible to dissect the 
specific contribution of the IMS fraction of G93A-SOD1 to the activation of the 
UPRmt, and revealed that this fraction is sufficient to promote the activation of 
OMI and the proteasome in females. In addition, the comparison between the 
G93A-SOD1 and G93A IMS-SOD1 models showed that the inhibition of the 
proteasome observed in males is mainly dependent on the cytosolic mutant 
SOD1. Further, since OMI and NRF-1 were higher in G93A IMS-SOD1 males 
than in the G93A-SOD1 mice, collectively these results support the notion that 
the IMS fraction of mutant SOD1 plays a direct role in the activation of the 
UPRmt. 
One of the most striking effects observed was the activation of OMI in 
G93A-SOD1 female mice. Interestingly, in sporadic ALS patient post-mortem 
studies, OMI was found to accumulate in spinal motor neurons (Kawamoto et 
al., 2010). On the other hand, a decrease in OMI was reported to contribute to 
neurodegeneration (Jones et al., 2003; Strauss et al., 2005; Moisoi et al., 
2009). In light of these findings, we propose that increased OMI levels induced 
by the UPRmt may enhance protein quality control in the IMS and delay the 
onset of mitochondrial damage. However, as mitochondrial damage 
progresses, despite its increase, OMI becomes insufficient to maintain the 
integrity of mitochondria. In fact, since release of OMI in the cytosol upon 
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mitochondrial outer membrane permeabilization plays a role in apoptosis, an 
initial protective effect of elevated OMI in the IMS could eventually contribute 
to the acceleration of cell death, if mitochondrial damage promotes its release 
into the cytosol. This could contribute possibly to the delay in disease 
progression in ALS female mice relative to males. 
Finally, our results in the ERαKO mice suggested that, as we previously 
reported in breast cancer cells (Papa and Germain, 2011), upon inhibition of 
the ERα the CHOP axis of the UPRmt could play a compensatory role in an 
attempt to maintain the integrity of the mitochondria. The UPRmt pathway is 
rapidly gaining attention, and this study is the first to identify activation of this 
pathway in a disease relevant model in vivo. Considering that the UPRmt 
regulates the communication between stressed mitochondria and the nucleus, 
it is likely to be implicated in the pathology of several diseases with 
mitochondrial involvement. Importantly, as some tissues and cell types do not 
express ERα and the function of the ERα is tissue specific (Bhat-Nakshatri et 
al., 2008) (Carroll et al., 2006) one interesting possible implication of our 
findings is that the UPRmt could help explain some aspects of the sex 
differences and cell type specificity observed in ALS. Clearly, more work 
needs to be done to determine if our findings in the SOD1 mouse model apply 
to humans affected by the much more common sporadic forms of ALS, but the 
higher incidence of sporadic ALS in males (McCombe and Henderson, 2010) 
suggests that estrogen hormones and their receptors could indeed be involved 
in sex differences through the ERα axis of the UPRmt. Moreover, considering 
that estrogen has been reported to affect the severity of primary mitochondrial 
diseases with strong male bias, such as Leber's hereditary optic neuropathy 
(Giordano et al., 2011), whether this pathway also plays a role in gender 
differences in these diseases remains to be explored. 
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